

### PERSONAL INFORMATION Aldo Pietro Maggioni

#### WORK EXPERIENCE

---

- January 1996- Present **Director of Research Center of Italian Association of Hospital Cardiologists (ANMCO), Florence, Italy**  
Fondazione per il Tuo cuore, Via La Marmora 36 (Italy)  
Planning, organizing and conducting clinical trials in cardiovascular care. Analysis and interpretation of their results.
- October 2018- Present **Vice President**  
ReS Foundation, Rome (Italy)
- January 2010- Present **Scientific Coordinator of the Euroobservational Research Programme (ESC) European Society of Cardiology (ESC) (France)**  
Planning, organizing and conducting observational research in cardiovascular disease. Analysis and interpretation of their results.
- 1994- 1995 **Co-director of the department of cardiovascular research**  
IRCCS Mario Negri Institute (Italy)  
Planning, organizing and conducting observational research in cardiovascular care. Analysis and interpretation of their results.
- 1992- 1994 **Vice Head**  
Division of Internal Medicine and Cardiology, General Hospital "Fatebenefratelli" (Italy)  
Periodically responsible for wards, coronary unit and electrophysiology lab
- 1988- 1992 **Vice Head**  
Division of Internal Medicine and Cardiology, General Hospital "G. Fornaroli" (Italy)  
Periodically responsible for wards, coronary unit and electrophysiology lab
- 1978- 1987 **Clinical Cardiologist**  
Division of Cardiology, General Hospital "G. Fornaroli" (Italy)  
Periodically responsible for wards, coronary unit and electrophysiology lab
- 1975- 1978 **Clinical Cardiologist**  
Emergency Room, Ospedale C. Cantù (Italy)  
Assistant in the emergency room of a public hospital with an area of approximately 300,000 inhabitants

#### EDUCATION AND TRAINING

---

- 1975- 1978 **Postgraduate degree in cardiovascular diseases**  
University of Padova (Italy)
- 1968- 1974 **Medical Degree**  
University of Milan (Italy)
- 1963- 1968 **High school diploma (classical studies)**  
Liceo Classico Berchet (Italy)

#### ADDITIONAL INFORMATION

---

## Year 2021

1. Sciattella P, Maggioni AP, Arcangeli E, Sidelnikov E, Kahangire DA, Mennini FS. Healthcare Resource Utilization, Cardiovascular Event Rate and Use of Lipid-Lowering Therapies in Secondary Prevention of ASCVD in Hospitalized Patients in Italy. *Adv Ther.* 2021 Oct 31. doi: 10.1007/s12325-021-01960-y. Epub ahead of print.
2. Calabria S, Ronconi G, Dondi L, Piccinni C, Cinconze E, Pedrini A, Esposito I, Addesi A, Martini N, Maggioni AP. Coronary Artery Disease in Patients Older than 35 and Eligible for Cardiovascular Secondary Prevention: An Italian Retrospective Observational Analysis of Healthcare Administrative Databases. *J Clin Med.* 2021 Oct 14;10(20):4708. doi: 10.3390/jcm10204708.
3. Calabria S, Piccinni C, Ronconi G, Dondi L, Pedrini A, Addesi A, Esposito I, Maggioni AP, Barbui C, Martini N. Antipsicotici di seconda generazione ed eventi cardio-metabolici: analisi real-world e costi assistenziali [Second-generation antipsychotics and cardio-metabolic events: real-world analysis and healthcare costs]. *Riv Psichiatr.* 2021 Sep-Oct;56(5):272-280. Italian. doi: 10.1708/3681.36675.
4. Levi N, Bongiorno MG, Rav Acha M, Tovia-Brodie O, Kennergren C, Auricchio A, Maggioni AP, Rinaldi CA, Nof E, Ilan M, Blomstrom-Lundqvist C, Deharo JC, Leclercq C, Glikson M, Michowitz Y. Lead fixation mechanism impacts outcome of transvenous lead extraction: Data from the European Lead Extraction ConTRolled Registry. *Europace.* 2021 Oct 15:euab240. doi: 10.1093/europace/euab240. Epub ahead of print.
5. Andreotti F, Maggioni AP, Campeggi A, Iervolino A, Scambia G, Massetti M. Anti-inflammatory therapy in ischaemic heart disease: from canakinumab to colchicine. *Eur Heart J Suppl.* 2021 Oct 8;23(Suppl E):E13-E18. doi: 10.1093/eurheartj/suab084.
6. Calabria S, Piccinni C, Ronconi G, Dondi L, Cinconze E, Esposito I, Addesi A, Pedrini A, Maggioni AP, Martini N. Uso cronico dell'associazione estemporanea ACE-inibitori e beta-bloccanti in Italia dal 2013 al 2019 attraverso i dati amministrativi sanitari [Chronic use of the unfixed combination of ACE-inhibitors and beta-blockers in Italy from 2013 to 2019 through the healthcare administrative data.]. *Recenti Prog Med.* 2021 Oct;112(10):678-686. Italian. doi: 10.1701/3679.36659.
7. Sierpinski R, Franczuk P, Tkaczyszyn M, Suchocki T, Krekora J, Opolski G, Maggioni A, Polonski L, Ponikowski P, Jankowska EA. Burden of multimorbidity in a Polish cohort of ambulatory and hospitalized heart failure patients from two large European registry programs: prognostic implications. *Pol Arch Intern Med.* 2021 Sep 29. doi: 10.20452/pamw.16101. Epub ahead of print.
8. Grand J, Miger K, Sajadieh A, Kober L, Torp-Pedersen C, Ertl G, Lopez-Sendon J, Pietro Maggioni A, Teerlink JR, Sato N, Gimpelewicz C, Metra M, Holbro T, Nielsen OW. Systolic Blood Pressure and Outcome in Patients Admitted With Acute Heart Failure: An Analysis of Individual Patient Data From 4 Randomized Clinical Trials. *J Am Heart Assoc.* 2021;10(18):e022288. doi: 10.1161/JAHA.121.022288. Epub 2021 Sep 13.
9. Signori C, Meessen JMTA, Laaksonen R, Maggioni AP, Novelli D, Blanda A, Jylha A, Nicolis E, Targher G, Tavazzi L, Tognoni G, Hilvo M, Latini R. Coffee, Atrial Fibrillation, and Circulating Ceramides in Patients with Chronic Heart Failure. *J Agric Food Chem.* 2021 Sep 17. doi: 10.1021/acs.jafc.1c03741. Epub ahead of print.
10. Newman JD, Anthopoulos R, Mancini GBJ, Bangalore S, Reynolds HR, Kunichoff DF, Senior R, Peteiro J, Bhargava B, Garg P, Escobedo J, Doerr R, Mazurek T, Gonzalez-Juanatey J, Gajos G, Briguori C, Cheng H, Vertes A, Mahajan S, Guzman LA, Keltai M, Maggioni AP, Stone GW, Berger JS, Rosenberg YD, Boden WE, Chaitman BR, Fleg JL, Hochman JS, Maron DJ. Outcomes of Participants with Diabetes in the ISCHEMIA Trials. *Circulation.* 2021 Sep 15. doi: 10.1161/CIRCULATIONAHA.121.054439. Epub ahead of print.
11. Tavazzi L, Maggioni AP, Rapezzi C, Ferrari R. One year on: The impact of COVID-19 on clinical research. *Eur J Intern Med* 2021;92:24-27. doi: 10.1016/j.ejim.2021.08.008. Epub 2021 Aug 25.
12. Maggioni AP, Andreotti F. Closing the Gap Between Populations Enrolled in Traditional Randomized Controlled Trials and Patients Encountered in Clinical Practice: The Case of Heart Failure. *Circ Heart Fail* 2021;14(9):e008840. doi: 10.1161/CIRCHEARTFAILURE.121.008840. Epub 2021 Aug 19.
13. Jackson AM, Jhund PS, Anand IS, Dungen HD, Lam CSP, Lefkowitz MP, Linssen G, Lund LH, Maggioni AP, Pfeffer MA, Rouleau JL, Saraiva JFK, Senni M, Vardeny O, Wijkman MO, Yilmaz MB, Saito Y, Zile MR, Solomon SD, McMurray JJV. Sacubitril-valsartan as a treatment for apparent resistant hypertension in patients with heart failure and preserved ejection fraction. *Eur Heart J* 2021;42:3741-3752. doi: 10.1093/eurheartj/ehab499.

14. Zeymer U, Ludman P, Danchin N, Kala P, Laroche C, Sadeghi M, Caporale R, Shaheen SM, Legutko J, Iakobsishvili Z, Alhabib KF, Motovska Z, Studencan M, Mimoso J, Becker D, Alexopoulos D, Kereseslidze Z, Stojkovic S, Zelveian P, Goda A, Mirrakhimov E, Bajraktari G, Al-Farhan H, Serpytis P, Raungaard B, Marandi T, Moore AM, Quinn M, Karjalainen PP, Tatu-Chitolu G, Gale CP, Maggioni AP, Weidinger F; ACVC EAPCI EORP ACS STEMI investigators group of the ESC. Reperfusion therapies and in-hospital outcomes for ST-elevation myocardial infarction in Europe: the ACVC-EAPCI EORP STEMI Registry of the European Society of Cardiology. *Eur Heart J*. 2021 Aug 14;ehab342. doi: 10.1093/eurheartj/ehab342. Epub ahead of print.
15. Lesen E, Hewitt C, Giannitsis E, Hedberg J, Jernberg T, Lambrelli D, Maggioni AP, Simeone JC, Ariza-Sole A, Storey RF, Ten Berg J, Bonaca M; ALETHEIA study team. Extended dual antiplatelet therapy with ticagrelor 60 mg in patients with prior myocardial infarction: The design of ALETHEIA, a multi-country observational study. *Clin Cardiol*. 2021 Aug 8. doi: 10.1002/clc.23702. Epub ahead of print.
16. Batra G, Aktaa S, Wallentin L, Maggioni AP, Wilkinson C, Casadei B, Gale CP. Methodology for the development of international clinical data standards for common cardiovascular conditions: European Unified Registries for Heart Care Evaluation and Randomised Trials (EuroHeart). *Eur Heart J Qual Care Clin Outcomes*. 2021 Aug 5;qcab052. doi: 10.1093/ehjqcco/qcab052. Epub ahead of print.
17. Andreotti F, Massetti M, Maggioni AP. Unexpected high mortality associated with very low lipoprotein(a) after acute myocardial infarction: Identifying the unknown. *Eur J Intern Med* 2021;91:26-28. doi: 10.1016/j.ejim.2021.07.006. Epub 2021 Jul 31.
18. Cereda A, Toselli M, Palmisano A, Vignale D, Leone R, Nicoletti V, Gnasso C, Mangieri A, Khokhar A, Campo G, Scoccia A, Bertini M, Loffi M, Sergio P, Andreini D, Pontone G, Iannopollo G, Nannini T, Ippolito D, Bellani G, Patelli G, Besana F, Vignali L, Sverzellati N, Iannaccone M, Vaudano PG, Sangiorgi GM, Turchio P, Monello A, Tumminello G, Maggioni AP, Rapezzi C, Colombo A, Giannini F, Esposito A. The hidden interplay between sex and COVID-19 mortality: the role of cardiovascular calcification. *Geroscience*. 2021 Jul 14:1-15. doi: 10.1007/s11357-021-00409-y. Epub ahead of print
19. Gori M, Senni M, Claggett B, Liu J, Maggioni AP, Zile M, Prescott MF, Van Veldhuisen DJ, Zannad F, Pieske B, Lam CSP, Rouleau J, Jhund P, Packer M, Pfeffer MA, Lefkowitz M, Shi V, McMurray JJV, Solomon SD. Integrating High-Sensitivity Troponin T and Sacubitril/Valsartan Treatment in HFpEF: The PARAGON-HF Trial. *JACC Heart Fail* 2021;9:627-635. doi: 10.1016/j.jchf.2021.04.009. Epub 2021 Jul 7.
20. Tyminska A, Ozieranski K, Balsam P, Kaplon-Cieslicka A, Maciejewski C, Marchel M, Crespo-Leiro MG, Maggioni AP, Drozd J, Filipiak KJ, Opolski G, Grabowski M. The prevalence and association of major ECG abnormalities with clinical characteristics and the outcomes of real-life heart failure patients-Heart Failure Registries of the ESC. *Kardiol Pol* 2021;79:980-987. doi: 10.33963/KP.a2021.0053. Epub 2021 Jul 6.
21. Maggioni AP, Dondi L, Andreotti F, Ronconi G, Calabria S, Piccinni C, Pedrini A, Esposito I, Martini N. Prevalence, prescriptions, outcomes and costs of type 2 diabetes patients with or without prior coronary artery disease or stroke: a longitudinal 5-year claims-data analysis of over 7 million inhabitants. *Ther Adv Chronic Dis*. 2021 Jun 22;12:20406223211026390. doi: 10.1177/20406223211026390.
22. Eikelboom JW, Bhatt DL, Fox KAA, Bosch J, Connolly SJ, Anand SS, Avezum A, Berkowitz SD, Branch KRH, Dagenais GR, Felix C, Guzik TJ, Hart RG, Maggioni AP, Muehlhofer E, Sharma M, Shestakovska O, Yusuf S. Mortality Benefit of Rivaroxaban Plus Aspirin in Patients With Chronic Coronary or Peripheral Artery Disease. *J Am Coll Cardiol* 2021;78:14-23. doi: 10.1016/j.jacc.2021.04.083.
23. Vanassche T, Verhamme P, Anand SS, Shestakovska O, Leong DP, Fox KAA, Bhatt DL, Avezum A, Alings M, Aboyans V, Maggioni AP, Widimsky P, Muehlhofer E, Berkowitz SD, Yusuf S, Connolly SJ, Eikelboom JW, Bosch J. Low-dose rivaroxaban plus aspirin in patients with polypharmacy and multimorbidity: an analysis from the COMPASS trial. *Eur Heart J Cardiovasc Pharmacother*. 2021 Jun 30;pvab050. doi: 10.1093/ehjcvp/pvab050. Epub ahead of print.
24. Esposito I, Calabria S, Piccinni C, Addesi A, Dondi L, Ronconi G, Pedrini A, Maggioni AP, Curigliano G, Listi A, Righi L, Novello S, Buglioni S, Ciliberto G, Pruneri G, Martini N. L'oncologia mutazionale del carcinoma polmonare: marcatori molecolari, farmaci, condizioni negoziali ed esperienze in centri di riferimento nazionale [Mutational oncology of lung cancer: molecular markers, drugs, negotiation conditions and experiences in national reference centers.]. *Recenti Prog Med* 2021;112:419-437. Italian. doi: 10.1701/3620.36025.

25. Jackson AM, Petrie MC, Frogoudaki A, Laroche C, Gustafsson F, Ibrahim B, Mebazaa A, Johnson MR, Seferovic PM, Regitz-Zagrosek V, Mbakwem A, Bohm M, Prameswari HS, Abdel Gawad DAF, Goland S, Damasceno A, Karaye K, Farhan HA, Hamdan R, Maggioni AP, Sliwa K, Bauersachs J, van der Meer P; PPCM Investigators Group. Hypertensive disorders in women with peripartum cardiomyopathy: insights from the ESC Peripartum Cardiomyopathy Registry. *Eur J Heart Fail*. 2021 Jun 11. doi: 10.1002/ejhf.2264. Epub ahead of print.
26. Cotter G, Davison BA, Edwards C, Senger S, Teerlink JR, Zannad F, Nielsen OW, Metra M, Mebazaa A, Chioncel O, Greenberg BH, Maggioni AP, Ertl G, Sato N, Cohen-Solal A. Regional variation of effects of new antidiabetic medications in cardiovascular outcome trials. *Am Heart J* 2021;240:73-80. doi: 10.1016/j.ahj.2021.06.001. Epub ahead of print.
27. Piccinni C, Cevoli S, Ronconi G, Dondi L, Calabria S, Pedrini A, Maggioni AP, Esposito I, Addesi A, Favoni V, Pierangeli G, Cortelli P, Martini N. Insights into real-world treatment of cluster headache through a large Italian database: prevalence, prescription patterns and costs. *Expert Rev Clin Pharmacol* 2021;14:1165-1171. doi: 10.1080/17512433.2021.1934448. Epub 2021 May 31.
28. Deidda M, Noto A, Dessalvi CC, Andreini D, Andreotti F, Ferrannini E, Latini R, Maggioni AP, Magnoni M, Maseri A, Mercurio G; CAPIRE Investigators. Metabolomic correlates of coronary atherosclerosis, cardiovascular risk, both or neither. Results of the 2\*2 phenotypic CAPIRE study. *Int J Cardiol* 2021;336:14-21. doi: 10.1016/j.ijcard.2021.05.033. Epub 2021 May 20.
29. Maggioni AP, Andreotti F. Efficacy of COVID-19 Vaccines Against Active Comparators or Inert Placebos. *JAMA Intern Med* 2021;181:1257-1258. doi: 10.1001/jamainternmed.2021.2124.
30. Pongiglione B, Torbica A, Gale CP, Tavazzi L, Vardas P, Maggioni AP. Patient, hospital and country-level risk factors of all-cause mortality among patients with chronic heart failure: Prospective international cohort study. *PLoS One*. 2021 May 10;16(5):e0250931. doi: 10.1371/journal.pone.0250931.
31. White HD, O'Brien SM, Alexander KP, Boden WE, Bangalore S, Li J, Manjunath CN, Lopez-Sendon JL, Peteiro J, Gosselin G, Berger JS, Maggioni AP, Reynolds HR, Hochman JS, Maron DJ. Comparison of Days Alive Out of Hospital With Initial Invasive vs Conservative Management: A Prespecified Analysis of the ISCHEMIA Trial. *JAMA Cardiol* 2021;6:1023-1031. doi: 10.1001/jamacardio.2021.1651.
32. Andreotti F, Iervolino A, Navarese EP, Maggioni AP, Crea F, Scambia G. Precision Phenomapping of Acute Coronary Syndromes to Improve Patient Outcomes. *J Clin Med* 2021;10:1755. doi: 10.3390/jcm10081755.
33. Tutarel O, Baris L, Budts W, Gamal Abd-El Aziz M, Liptai C, Majdalany D, Jovanova S, Frogoudaki A, Connolly HM, Johnson MR, Maggioni AP, Hall R, Roos-Hesselink JW; ROPAC Investigators Group. Pregnancy outcomes in women with a systemic right ventricle and transposition of the great arteries results from the ESC-EORP Registry of Pregnancy and Cardiac disease (ROPAC). *Heart*. 2021 Apr 28;heartjnl-2020-318685. doi: 10.1136/heartjnl-2020-318685. Epub ahead of print.
34. Johansson I, Joseph P, Balasubramanian K, McMurray JJV, Lund LH, Ezekowitz JA, Kamath D, Alhabib K, Bayes-Genis A, Budaj A, Dans ALL, Dzudie A, Probstfield JL, Fox KAA, Karaye KM, Makubi A, Fukakusa B, Teo K, Temizhan A, Wittlinger T, Maggioni AP, Lanan F, Lopez-Jaramillo P, Silva-Cardoso J, Sliwa K, Dokainish H, Grinvalds A, McCready T, Yusuf S. Health-Related Quality of Life and Mortality in Heart Failure: The Global Congestive Heart Failure Study of 23,000 Patients from 40 Countries. *Circulation* 2021;143:2129-2142. doi: 10.1161/CIRCULATIONAHA.120.050850. Epub 2021 Apr 28.
35. Ambrosio G, Leiro MGC, Lund LH, Coiro S, Cardona A, Filippatos G, Ferrari R, Piepoli MF, Coats AJS, Anker SD, Laroche C, Almenar-Bonet L, Poder P, Valero DB, Frisinghelli A, Maggioni AP. Serum uric acid and outcomes in patients with chronic heart failure through the whole spectrum of ejection fraction phenotypes: Analysis of the ESC-EORP Heart Failure Long-Term (HF LT) Registry. *Eur J Intern Med* 2021;89:65-75. doi: 10.1016/j.ejim.2021.04.001. Epub 2021 Apr 23.
36. Andreotti F, Maggioni AP, Scambia G. Sex- and gender specific precision medicine for chronic coronary syndromes: challenges and opportunities. *Kardiol Pol* 2021;79:373-375. doi: 10.33963/KP.15948. Epub 2021 Apr 23.
37. Shen L, Jhund PS, Anand IS, Bhatt AS, Desai AS, Maggioni AP, Martinez FA, Pfeffer MA, Rizkala AR, Rouleau JL, Swedberg K, Vaduganathan M, Vardeny O, van Veldhuisen DJ, Zannad F, Zile MR, Packer M, Solomon SD, McMurray JJV. Incidence and Outcomes of Pneumonia in Patients With Heart Failure. *J Am Coll Cardiol* 2021;77:1961-1973. doi: 10.1016/j.jacc.2021.03.001.
38. Tromp J, Claggett BL, Liu J, Jackson AM, Jhund PS, Kober L, Widimsky J, Boytsov SA, Chopra VK, Anand IS, Ge J, Chen CH, Maggioni AP, Martinez F, Packer M, Pfeffer MA, Pieske B, Redfield

- MM, Rouleau JL, Van Veldhuisen DJ, Zannad F, Zile MR, Rizkala AR, Inubushi-Molessa A, Lefkowitz MP, Shi VC, McMurray JJV, Solomon SD, Lam CSP; PARAGON-HF Investigators. Global Differences in Heart Failure With Preserved Ejection Fraction: The PARAGON-HF Trial. *Circ Heart Fail* 2021;14(4):e007901. doi: 10.1161/CIRCHEARTFAILURE.120.007901. Epub 2021 Apr 19.
39. Maggioni AP, Iervolino A, Andreotti F. Is it time to introduce anti-inflammatory drugs into secondary cardiovascular prevention: evidence from clinical trials? *Vessel Plus* 2021;5:14. DOI: 10.20517/2574-1209.2021.05
40. Jering KS, Claggett B, Pfeffer MA, Granger C, Kober L, Lewis EF, Maggioni AP, Mann D, McMurray JJV, Rouleau JL, Solomon SD, Steg PG, van der Meer P, Wernsing M, Carter K, Guo W, Zhou Y, Lefkowitz M, Gong J, Wang Y, Merkely B, Macin SM, Shah U, Nicolau JC, Braunwald E. Prospective ARNI versus ACE inhibitor trial to Determine Superiority in reducing heart failure Events after Myocardial Infarction (PARADISE-MI): Design and Baseline Characteristics. *Eur J Heart Fail* 2021;23:1040-1048. doi: 10.1002/ejhf.2191. Epub 2021 Apr 22.
41. Maggioni AP, Dondi L, Andreotti F, Calabria S, Iacoviello M, Gorini M, Gonzini L, Piccini C, Ronconi G, Martini N. Prevalence, clinical impact and costs of hyperkalaemia: Special focus on heart failure. *Eur J Clin Invest* 2021;51:e13551. doi: 10.1111/eci.13551. Epub 2021 Mar 31.
42. Russo G, Monami M, Perseghin G, Avogaro A, Perrone Filardi P, Senni M, Borghi C, Maggioni AP. The "Early Treatment" Approach Reducing Cardiovascular Risk in Patients with Type 2 Diabetes: A Consensus From an Expert Panel Using the Delphi Technique. *Diabetes Ther* 2021;12:1445-1461. doi: 10.1007/s13300-021-01045-7. Epub 2021 Mar 25.
43. Giannini F, Toselli M, Palmisano A, Cereda A, Vignale D, Leone R, Nicoletti V, Gnasso C, Monello A, Manfrini M, Khokhar A, Sticchi A, Biagi A, Turchio P, Tacchetti C, Landoni G, Boccia E, Campo G, Scoccia A, Ponticelli F, Danzi GB, Loffi M, Muri M, Pontone G, Andreini D, Mancini EM, Casella G, Iannopolo G, Nannini T, Ippolito D, Bellani G, Franzesi CT, Patelli G, Besana F, Costa C, Vignali L, Benatti G, Sverzellati N, Scarnecchia E, Lombardo FP, Anastasio F, Iannaccone M, Vaudano PG, Pacielli A, Baffoni L, Gardi I, Cesini E, Sperandio M, Micossi C, De Carlini CC, Spreafico C, Maggiolini S, Bonaffini PA, Iacovoni A, Sironi S, Senni M, Fominskiy E, De Cobelli F, Maggioni AP, Rapezzi C, Ferrari R, Colombo A, Esposito A. Coronary and total thoracic calcium scores predict mortality and provides pathophysiologic insights in COVID-19 patients. *J Cardiovasc Comput Tomogr* 2021;15:421-430. doi: 10.1016/j.jcct.2021.03.003. Epub 2021 Mar 11.
44. Ferrara P, Cortesi PA, Di Laura D, Maggioni AP, Mantovani LG. Cost-Effectiveness Analysis of Rivaroxaban Plus Aspirin Compared with Aspirin Alone in Patients with Coronary and Peripheral Artery Diseases in Italy. *Clin Drug Investig* 2021; 41:459-468. doi: 10.1007/s40261-021-01023-8. Epub 2021 Mar 16.
45. Zeymer U, Clark AL, Barrios V, Damy T, Drozd J, Fonseca C, Lund LH, Kalus S, Ferber PC, Hussain RI, Koch C, Maggioni AP; ARIADNE investigators. Utilisation of sacubitril/valsartan in patients with heart failure with reduced ejection fraction: Real world data from the ARIADNE registry. *Eur Heart J Qual Care Clin Outcomes*. 2021 Mar 16:qcab019. doi: 10.1093/ehjqcco/qcab019. Epub ahead of print.
46. Sidhu BS, Gould J, Elliott M, Mehta V, Kennergren C, Butter C, Deharo JC, Kutarski A, Maggioni AP, Auricchio A, Kuck KH, Blomstrom-Lundqvist C, Bongiorno MG, Rinaldi CA. The effect of centre volume and procedure location on major complications and mortality from transvenous lead extraction: an ESC EHRA EORP European Lead Extraction ConTrolled ELECTRa Registry subanalysis-Author's reply. *Europace*. 2021 Jul 18;23(7):1149-1150. doi: 10.1093/europace/euab039.
47. Rossello X, Bueno H, Gil V, Jacob J, Martin-Sanchez FJ, Llorens P, Herrero Puente P, Alquezar-Arbe A, Espinosa B, Raposeiras-Roubin S, Muller CE, Mebazaa A, Maggioni AP, Pocock S, Chioncel O, Miro O; ICA-SEMES Research Group. Synergistic Impact of Systolic Blood Pressure and Perfusion Status on Mortality in Acute Heart Failure. *Circ Heart Fail* 2021; 14(3):e007347. doi: 10.1161/CIRCHEARTFAILURE.120.007347. Epub 2021 Mar 8.
48. Cattaneo D, Pasina L, Maggioni AP, Oreni L, Conti F, Pezzati L, Casalini G, Bonazzetti C, Morena V, Ridolfo A, Antinori S, Gervasoni C. Drug-Drug Interactions and Prescription Appropriateness at Hospital Discharge: Experience with COVID-19 Patients. *Drugs Aging* 2021;38:341-346. doi: 10.1007/s40266-021-00840-y. Epub 2021 Mar 1.
49. Seferovic PM, Vardas P, Jankowska EA, Maggioni AP, Timmis A, Milinkovic I, Polovina M, Gale CP, Lund LH, Lopatin Y, Lainscak M, Savarese G, Huculeci R, Kazakiewicz D, Coats AJ; Developed in collaboration with the National Heart Failure Societies of the ESC member countries, Berger R, Jahangirov T, Kurlianskaya A, Troisfontaines P, Droogne W, Hudic LD, Tokmakova M, Glavas D, Barberis V, Spinar J, Wolsk E, Uetoa T, Tolppanen H, Kipiani Z, Stork S, Bauersachs J, Keramida K, Parissis J, Habon T, Gotsman I, Weinstein JM, Ingimarsdottir IJ, Crowley J, Dalton B, Aspromonte N, Nodari S, Volterrani M, Rakisheva A, Mirrakhimov E, Kamzola G, Skouri H,

- Celutkiene J, Jovanova S, Vataman E, Cobac IP, Van Pol P, De Boer R, von Lueder T, Straburzynska-Migaj E, Moura B, Chioncel O, Fomin I, Begrambekova J, Lopatin Y, Mareev Y, Goncalvesova E, Seferovic P, Milinkovic I, Lainscak M, Pinilla JMG, Lindmark K, Mueller C, Cavusoglu Y, Gardner R, Voronkov L. The Heart Failure Association Atlas: Heart Failure Epidemiology and Management Statistics 2019. *Eur J Heart Fail.* 2021 Jun;23(6):906-914. doi: 10.1002/ejhf.2143. Epub 2021 Mar 13.
50. Sidhu BS, Ayis S, Gould J, Elliott MK, Mehta V, Kennergren C, Butter C, Deharo JC, Kutarski A, Maggioni AP, Auricchio A, Kuck KH, Blomstrom-Lundqvist C, Bongioni MG, Rinaldi CA; ELECTRa Investigators Group. Risk stratification of patients undergoing transvenous lead extraction with the ELECTRa Registry Outcome Score (EROS): an ESC EHRA EORP European lead extraction ConTRolled ELECTRa registry analysis. *Europace* 2021; 23:1462-1471. doi: 10.1093/europace/euab037.
51. Chioncel O, Ambrosy AP, Maggioni AP. Temporal Trends in the Outcomes of Acute Heart Failure: Between Consolatory Evidences and Real Progress. *Eur J Heart Fail* 2021;23:432-435. doi: 10.1002/ejhf.2130. Epub 2021 Feb 26.
52. Alings M, Descamps O, Guillon B, Leosdottir M, Maggioni AP, Recasens L, Speidl WS, Tripodi RV, Landmesser U, Catapano AL, Pirillo A. Implementation of clinical practices and pathways optimizing ACS patients lipid management: Focus on eight European initiatives. *Atheroscler Suppl.* 2020 Dec;42:e59-e64. doi: 10.1016/j.atherosclerosissup.2021.01.010.
53. Dube MP, Legault MA, Lemacon A, Lemieux Perreault LP, Fouodjio R, Waters DD, Kouz S, Pinto FJ, Maggioni AP, Diaz R, Berry C, Koenig W, Lopez-Sendon J, Gamra H, Kiwan GS, Asselin G, Provost S, Barhdadi A, Sun M, Cossette M, Blondeau L, Mongrain I, Dubois A, Rhainds D, Bouabdallaoui N, Samuel M, de Denus S, L'Allier PL, Guertin MC, Roubille F, Tardif JC. Pharmacogenomics of the Efficacy and Safety of Colchicine in COLCOT. *Circ Genom Precis Med* 2021;14:e003183. doi: 10.1161/CIRCGEN.120.003183. Epub 2021 Feb 9.
54. Asselbergs FW, Sammani A, Elliott P, Gimeno JR, Tavazzi L, Tendera M, Kaski JP, Maggioni AP, Rubis PP, Jurcut R, Helio T, Calo L, Sinagra G, Zdravkovic M, Olivotto I, Kavoluniene A, Laroche C, Caforio ALP, Charron P; Cardiomyopathy & Myocarditis Registry Investigators Group. Differences between familial and sporadic dilated cardiomyopathy: ESC EORP Cardiomyopathy & Myocarditis registry. *ESC Heart Fail* 2021;8:95-105.
55. Mizia-Stec K, Charron P, Gimeno Blanes JR, Elliott P, Kaski JP, Maggioni AP, Tavazzi L, Tendera M, Felix SB, Dominguez F, Ojrzynska N, Losi MA, Limongelli G, Barriales-Villa R, Seferovic PM, Biagini E, Wybraniec M, Laroche C, Caforio ALP; EORP Cardiomyopathy Registry Investigators. Current use of cardiac magnetic resonance in tertiary referral centres for the diagnosis of cardiomyopathy: the ESC EORP Cardiomyopathy/Myocarditis Registry. *Eur Heart J Cardiovasc Imaging* 2021;22:781-789. doi: 10.1093/ehjci/jeaa329.
56. Galderisi S, De Hert M, Del Prato S, Fagiolini A, Gorwood P, Leucht S, Maggioni AP, Mucci A, Arango C. Identification and management of cardiometabolic risk in subjects with schizophrenia spectrum disorders: A Delphi expert consensus study. *Eur Psychiatry* 2021;64(1):e7. doi: 10.1192/j.eurpsy.2020.115.
57. Maggioni AP, Grego S. The 70/30 Rule Between Men and Women-Disparity or Opportunity? *JAMA Cardiol* 2021;6(4):481-482. doi: 10.1001/jamacardio.2020.6118.
58. Maggioni AP. How to appropriately update practicing clinicians on innovations in heart failure therapy waiting for the new version of the guidelines? *Int J Cardiol* 2021;329:148-149. doi: 10.1016/j.ijcard.2020.12.042. Epub 2020 Dec 24.
59. Andreotti F, Gervasoni C, Di Pasquale G, Maggioni AP. Methodological education in response to the quality of COVID-19 publications. *Pharmacol Res* 2021;164:105381. doi: 10.1016/j.phrs.2020.105381. Epub ahead of print.
60. Maggioni AP. Prevenzione secondaria della cardiopatia ischemica nella pratica clinica: i target terapeutici da tre diventano quattro, e a basso costo. *G Ital Cardiol* 2021;22(1):33-35
- Year 2020
1. Tutarel O, Ramlakhan KP, Baris L, Subirana MT, Bouchardy J, Nemes A, Vejlstrop NG, Osipova OA, Johnson MR, Hall R, Roos-Hesselink JW; ROPAC (Registry of Pregnancy and Cardiac Disease) Investigators Group \*. Pregnancy Outcomes in Women After Arterial Switch Operation for Transposition of the Great Arteries: Results From ROPAC (Registry of Pregnancy and Cardiac Disease) of the European Society of Cardiology EURObservational Research Programme. *J Am Heart Assoc.* 2020 Dec 22:e018176. doi: 10.1161/JAHA.120.018176. Epub ahead of print. [collaborators]
2. ESC Cardiovascular Realities 2020. An Illustrated Atlas of Key European Statistics. 2020. European Heart Agency. ISBN: 978-2-492212-00-0. EAN: 9782492212000

3. WHO Solidarity Trial Consortium, Pan H, Peto R, Henao-Restrepo AM, Preziosi MP, Sathiyamoorthy V, Abdool Karim Q, Alejandria MM, Hernandez Garcia C, Kieny MP, Malekzadeh R, Murthy S, Reddy KS, Roses Periago M, Abi Hanna P, Ader F, Al-Bader AM, Alhasawi A, Allum E, Alotaibi A, Alvarez-Moreno CA, Appadoo S, Asiri A, Aukrust P, Barratt-Due A, Bellani S, Branca M, Cappel-Porter HBC, Cerrato N, Chow TS, Como N, Eustace J, Garcia PJ, Godbole S, Gotuzzo E, Griskevicius L, Hamra R, Hassan M, Hassany M, Hutton D, Irmansyah I, Jancoriene L, Kirwan J, Kumar S, Lennon P, Lopardo G, Lydon P, Magrini N, Maguire T, Manevska S, Manuel O, McGinty S, Medina MT, Mesa Rubio ML, Miranda-Montoya MC, Nel J, Nunes EP, Perola M, Portoles A, Rasmin MR, Raza A, Rees H, Reges PPS, Rogers CA, Salami K, Salvadori MI, Sinani N, Sterne JAC, Stevanovikj M, Tacconelli E, Tikkinen KAO, Trelle S, Zaid H, Rottingen JA, Swaminathan S. Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results. *N Engl J Med*. 2020 Dec 2. doi: 10.1056/NEJMoa2023184. Epub ahead of print. [DSMB chair]
4. Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P, Kolkhof P, Nowack C, Schloemer P, Joseph A, Filippatos G; FIDELIO-DKD Investigators. Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. *N Engl J Med* 2020;383:2219-2229. [collaborators]
5. Trevisan R, Grosu A, Avogaro A, Agostoni P, Ceconi C, Genovese S, Bossi A, Piti A, Senni M, Maggioni AP. Grey zones sul diabete mellito in ambito cardiologico. Opinioni degli esperti. *G Ital Cardiol* 2020;21(12):916-922
6. Tavazzi L, Tognoni G, Maggioni AP. In ricordo di Peter Sleight, un geniale amico di tutti noi. Molti l'hanno conosciuto, alcuni meglio e gli hanno voluto molto bene. *G Ital Cardiol* 2020;21(12):990-991.
7. Asselbergs FW, Sammani A, Elliott P, Gimeno JR, Tavazzi L, Tendera M, Kaski JP, Maggioni AP, Rubis PP, Jurcut R, Helio T, Calo L, Sinagra G, Zdravkovic M, Olivotto I, Kavaliuniene A, Laroche C, Caforio ALP, Charron P; Cardiomyopathy & Myocarditis Registry Investigators Group. Differences between familial and sporadic dilated cardiomyopathy: ESC EORP Cardiomyopathy & Myocarditis registry. *ESC Heart Fail*. 2020 Nov 11. doi: 10.1002/ehf2.13100. Epub ahead of print.
8. Cattaneo D, Pasina L, Maggioni AP, Giacomelli A, Oreni L, Covizzi A, Bradanini L, Schiuma M, Antinori S, Ridolfo A, Gervasoni C. Drug-Drug Interactions and Prescription Appropriateness in Patients with COVID-19: A Retrospective Analysis from a Reference Hospital in Northern Italy. *Drugs Aging*. 2020 Nov 5. doi: 10.1007/s40266-020-00812-8. Epub ahead of print.
9. Vassilikos VP, Pagourelis ED, Laroche C, Blomstrom-Lundqvist C, Kautzner J, Maggioni AP, Tavazzi L, Dagnes N, Brugada J, Stuhlinger M, Arbelo E; AFA LT registry investigators group. Impact of centre volume on atrial fibrillation ablation outcomes in Europe: a report from the ESC EHRA EORP Atrial Fibrillation Ablation Long-Term (AFA LT) Registry. *Europace*. 2020 Nov 3:euaa236. doi: 10.1093/europace/euaa236. Epub ahead of print.
10. Margonato D, Mazzetti S, De Maria R, Gorini M, Iacoviello M, Maggioni AP, Mortara A. Heart Failure With Mid-range or Recovered Ejection Fraction: Differential Determinants of Transition. *Card Fail Rev* 2020 Oct 16;6:e28. doi: 10.15420/cfr.2020.13.
11. Ramlakhan KP, Tobler D, Greutmann M, Schwerzmann M, Baris L, Yetman AT, Nihoyannopoulos P, Manga P, Boersma E, Maggioni AP, Johnson MR, Hall R, Roos-Hesselink JW; ROPAC investigators group. Pregnancy outcomes in women with aortic coarctation. *Heart*. 2020 Oct 29;heartjnl-2020-317513. doi: 10.1136/heartjnl-2020-317513. Epub ahead of print.
12. Rapezzi C, Maggioni AP, Ferrari R. Adapting to survive. *Eur Heart J*. 2020 Oct 28;ehaa675. doi: 10.1093/eurheartj/ehaa675. Epub ahead of print.
13. Pedrini A, Piccinni C, Maggioni AP, Carle F, Corrao G. Nuovi farmaci per le patologie croniche. Individuazione delle popolazioni target con i real world data [New drugs for chronic diseases. Identification of target populations with real world data.]. *Recenti Prog Med* 2020;111:571-576.
14. Maggioni AP. Sex and gender: risposta [Sex and gender: reply]. *G Ital Cardiol (Rome)* 2020;21:905-906.
15. Wijkman MO, Claggett B, Diaz R, Gerstein HC, Kober L, Lewis E, Maggioni AP, Wolsk E, Aguilar D, Bentley-Lewis R, McMurray JJ, Probstfield J, Riddle M, Tardif JC, Solomon SD, Pfeffer MA. Blood pressure and mortality in patients with type 2 diabetes and a recent coronary event in the ELIXA trial. *Cardiovasc Diabetol* 2020;19(1):175. doi: 10.1186/s12933-020-01150-0.
16. Gimeno JR, Elliott PM, Tavazzi L, Tendera M, Kaski JP, Laroche C, Barriales-Villa R, Seferovic P, Biagini E, Arbustini E, Rocha-Lopes L, Linhart A, Mogensen J, Hagege A, Espinosa MA, Saad A, Maggioni AP, Caforio ALP, Charron P; EORP Cardiomyopathy Registry Investigators group. Prospective follow-up in various subtypes of cardiomyopathies: Insights from the ESC EORP Cardiomyopathy Registry. *Eur Heart J Qual Care Clin Outcomes*. 2020 Oct 9;qcaa075. doi: 10.1093/ehjqcco/qcaa075. Epub ahead of print.

17. Crespo-Leiro MG, Barge-Caballero E, Segovia-Cubero J, Gonzalez-Costello J, Bayes-Genis A, Lopez-Fernandez S, Mirabet-Perez S, Sanz-Julve M, Fernandez-Vivancos C, Perez-Ruiz JM, Garcia-Pinilla JM, Varela-Roman A, Almenar-Bonet L, Lara-Padron A, la Fuente-Galan L, Torres-Calvo F, Arias-Castano JC, Ridocci-Soriano F, Andres-Novales J, Pascual-Figal DA, Bierge-Valero D, Epelde F, Gallego-Page JC, Sahuquillo-Martinez AM, Diaz-Molina B, Dalmau Gonzalez-Gallarza R, Quiles-Granado J, Maggioni AP, Lund LH, Laroche C, Delgado-Jimenez J. Pronostico al ano en pacientes con insuficiencia cardiaca en Espana. Registro ESC-EORP-HFA Heart Failure Long-Term [One-year prognosis of patients with heart failure in Spain. ESC-EORP-HFA Heart Failure Long-Term Registry]. REC: CardioClinics 2020; Available online 24 June 2020. <https://doi.org/10.1016/j.rccl.2020.02.001>
18. Proietti M, Lip GYH, Laroche C, Fauchier L, Marin F, Nabauer M, Potpara T, Dan GA, Kalarus Z, Tavazzi L, Maggioni AP, Boriani G; ESC-EORP Atrial Fibrillation General Long-Term Registry Investigators Group. Relation of outcomes to ABC (Atrial Fibrillation Better Care) pathway adherent care in European patients with atrial fibrillation: an analysis from the ESC-EHRA EORP Atrial Fibrillation General Long-Term (AFGen LT) Registry. *Europace*. 2020 Oct 2:euaa274. doi: 10.1093/europace/euaa274. Epub ahead of print.
19. Sharma M, Hart RG, Smith EE, Bosch J, Eikelboom JW, Connolly SJ, Dyal L, Reeh KW, Casanova A, Diaz R, Lopez-Jaramillo P, Ertl G, Stork S, Dagenais GR, Lonn EM, Ryden L, Tonkin AM, Varigos JD, Bhatt DL, Branch KRH, Probstfield JL, Kim JH, O'Donnell M, Vinereanu D, Fox KAA, Liang Y, Liu L, Zhu J, Pogossova N, Maggioni AP, Avezum A, Piegas LS, Keltai K, Keltai M, Berkowitz SD, Yusuf S. Rivaroxaban for Prevention of Covert Brain Infarcts and Cognitive Decline: The COMPASS MRI Substudy. *Stroke* 2020;51(10):2901-2909. doi: 10.1161/STROKEAHA.120.029762.
20. Mizia-Stec K, Caforio ALP, Charron P, Gimeno JR, Elliott P, Kaski JP, Maggioni AP, Tavazzi L, Rigopoulos AG, Laroche C, Frigy A, Zachara E, Pena-Pena ML, Olusegun-Joseph A, Pinto Y, Sala S, Drago F, Blagova O, Reznik E, Tendera M. Atrial fibrillation, anticoagulation management and risk of stroke in the Cardiomyopathy/Myocarditis registry of the EURObservational Research Programme of the European Society of Cardiology. *ESC Heart Fail*. 2020 Sep 17. doi: 10.1002/ehf2.12854. Online ahead of print.
21. Lopes RD, Alexander KP, Stevens SR, Reynolds HR, Stone GW, Pina IL, Rockhold FW, Elghamazi A, Lopez-Sendon JL, Farsky PS, Chernyavskiy AM, Diaz A, Phaneuf D, DeBelder MA, Ma YT, Guzman LA, Khouri M, Sionis A, Hausenloy DJ, Doerr R, Selvanayagam JK, Maggioni AP, Hochman JS, Maron DJ. Initial Invasive versus Conservative Management of Stable Ischemic Heart Disease Patients with a History of Heart Failure or Left Ventricular Dysfunction: Insights from the ISCHEMIA Trial. *Circulation*. 2020 Aug 29. doi: 10.1161/CIRCULATIONAHA.120.050304. Online ahead of print.
22. Bouabdallaoui N, Tardif JC, Waters DD, Pinto FJ, Maggioni AP, Diaz R, Berry C, Koenig W, Lopez-Sendon J, Gamra H, Kiwan GS, Blondeau L, Orfanos A, Ibrahim R, Gregoire JC, Dube MP, Samuel M, Morel O, Lim P, Bertrand OF, Kouz S, Guertin MC, L'Allier PL, Roubille F. Time-to-treatment initiation of colchicine and cardiovascular outcomes after myocardial infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT). *Eur Heart J*. 2020 Aug 29;ehaa659. doi: 10.1093/eurheartj/ehaa659. Online ahead of print.
23. Di Pasquale G, Maggioni AP, Gervasoni C, Andreotti F. Trials and tribulations of coronavirus disease-2019 research: with a few bright lights in the fog. *J Cardiovasc Med (Hagerstown)* 2020;21(11):841-844. doi: 10.2459/JCM.0000000000001099.
24. Maggioni AP. Maintaining the balance between benefits and risks: The example of hyperkalemia in patients with heart failure. *Rev Port Cardiol* 2020; 39:543-544.
25. Aktaa S, Batra G, Wallentin L, Baigent C, Erlinge D, James S, Ludman P, Maggioni AP, Price S, Weston C, Casadei B, Gale CP. European Society of Cardiology methodology for the development of quality indicators for the quantification of cardiovascular care and outcomes. *Eur Heart J Qual Care Clin Outcomes*. 2020 Aug 26;qcaa069. doi: 10.1093/ehjqcco/qcaa069.
26. Sliwa K, Petrie MC, van der Meer P, Mebazaa A, Hilfiker-Kleiner D, Jackson AM, Maggioni AP, Laroche C, Regitz-Zagrosek V, Schaufelberger M, Tavazzi L, Roos-Hesselink JW, Seferovic P, van Spaendonck-Zwarts K, Mbakwem A, Bohm M, Mouquet F, Pieske B, Johnson MR, Hamdan R, Ponikowski P, Van Veldhuisen DJ, McMurray JJV, Bauersachs J. Clinical presentation, management, and 6-month outcomes in women with peripartum cardiomyopathy: an ESC EORP registry. *Eur Heart J* 2020;41:3787-3797. doi: 10.1093/eurheartj/ehaa455.
27. Gulizia MM, Maggioni AP, Abrignani MG, Bilato C, Mangiacapra F, Sanchez FA, Piovaccari G, Montagna L, Marini M, De Biasio M, Averna M, Casula M, Colivicchi F, Fabbri G, Lucci D, Zampoleri V, Catapano AL; POSTER Investigators. Prevalence Of familial hypercholesterolaemia (FH) in



- Italian Patients with coronary artERy disease: The POSTER study. *Atherosclerosis* 2020;308:32-38. doi: 10.1016/j.atherosclerosis.2020.07.007.
28. Helio T, Elliott P, Koskenvuo JW, Gimeno JR, Tavazzi L, Tendera M, Kaski JP, Mansencal N, Bilinska Z, Carr-White G, Damy T, Frustaci A, Kindermann I, Ripoll-Vera T, Celutkienė J, Axelsson A, Lorenzini M, Saad A, Maggioni AP, Laroche C, Caforio ALP, Charron P; EORP Cardiomyopathy Registry Investigators Group. ESC EORP Cardiomyopathy Registry: real-life practice of genetic counselling and testing in adult cardiomyopathy patients. *ESC Heart Fail* 2020;7(5):3013-21. doi: 10.1002/ehf2.12925.
29. Cioffi G, Giorda CB, Lucci D, Nada E, Ognibeni F, Mancusi C, Latini R, Maggioni AP on behalf of DYDA 2 Investigators. Effects of Dipeptidyl peptidase-4 inhibitor linagliptin on left ventricular DYsfunction in patients with type 2 DiAbetes and concentric left ventricular geometry. Results of the double-blind randomized controlled DYDA 2 trial. *Eur J Prev Cardiol.* 2020 Jul 28:2047487320939217. doi: 10.1177/2047487320939217. Online ahead of print.
30. Sidhu BS, Gould J, Bunce C, Elliott M, Mehta V, Kennergren C, Butter C, Deharo JC, Kutarski A, Maggioni AP, Auricchio A, Kuck KH, Blomstrom-Lundqvist C, Bongiorno MG, Rinaldi CA; ELECTRa Investigators Group. The effect of centre volume and procedure location on major complications and mortality from transvenous lead extraction: an ESC EHRA EORP European Lead Extraction ConTRolled ELECTRa registry subanalysis. *Europace.* 2020 Jul 20:euaa131. doi: 10.1093/europace/euaa131. Online ahead of print.
31. Grego S, Pasotti E, Moccetti T, Maggioni AP. "Sex and Gender medicine": il principio della medicina di genere. *G Ital Cardiol (Rome)* 2020; 21(8):602-606.
32. Joseph P, Dokainish H, McCready T, Budaj A, Roy A, Ertl G, Gomez-Mesa JE, Leong D, Ezekowitz J, Hage C, Lanas F, Maggioni AP, Sliwa K, Zhu J, Rouleau J, Balasubramanian K, Yusuf S; G-CHF Investigators. A multinational registry to study the characteristics and outcomes of heart failure patients: The global congestive heart failure (G-CHF) registry. *Am Heart J* 2020;227:56-63. doi: 10.1016/j.ahj.2020.06.002.
33. Targher G, Lunardi G, Mantovani A, Meessen J, Bonapace S, Temporelli PL, Nicolis E, Novelli D, Conti A, Tavazzi L, Maggioni AP, Latini R. Relation between plasma ceramides and cardiovascular death in chronic heart failure: A subset analysis of the GISSI-HF trial. *ESC Heart Fail.* 2020 Jul 6. doi: 10.1002/ehf2.12885. Online ahead of print
34. Kaplon-Cieslicka A, Laroche C, Crespo-Leiro MG, Coats AJS, Anker SD, Filippatos G, Maggioni AP, Hage C, Lara-Padron A, Fucili A, Drozd J, Seferovic P, Rosano GMC, Mebazaa A, McDonagh T, Lainscak M, Ruschitzka F, Lund LH and on behalf of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC) and the ESC Heart Failure Long-Term Registry Investigators. Is heart failure misdiagnosed in hospitalized patients with preserved ejection fraction? From the European Society of Cardiology - Heart Failure Association EURObservational Research Programme Heart Failure Long-Term Registry. *ESC Heart Fail* 2020;7(5):2098-112. doi: 10.1002/ehf2.12817. Online ahead of print.
35. Maggioni AP, Andreotti F, Gervasoni C, Di Pasquale G. COVID-19 trials in Italy: A call for simplicity, top standards and global pooling. *Int J Cardiol* 2020;318:160-164.
36. Conte E, Andreini D, Magnoni M, Masson S, Mushtaq S, Berti S, Canestrari M, Casolo G, Gabrielli D, Latini R, Marraccini P, Moccetti T, Modena MG, Pontone G, Gorini M, Maggioni AP, Maseri A; CAPIRE Investigators, Steering Committee; Imaging Core Laboratory; Centralized biobank and biomarker core laboratory; Central ECG Reading; Psychologists CRF Group; Participating Centers and Investigators. Association of high-risk coronary atherosclerosis at CCTA with clinical and circulating biomarkers: Insight from CAPIRE study. *J Cardiovasc Comput Tomogr.* 2020 Jun 11:S1934-5925(20)30128-3. doi: 10.1016/j.jcct.2020.03.005. Online ahead of print.
37. Potpara TS, Lip GYH, Dagres N, Crijns HJMG, Boriani G, Kirchhof P, Arbelo E, Savelieva I, Lenarczyk R, Fauchier L, Maggioni AP, Gale CP; EORP-AF III Investigators Group. Cohort profile The ESC EURObservational Research Programme Atrial Fibrillation III (AF III) Registry. *Eur Heart J Qual Care Clin Outcomes.* 2020 Jun 8;qcaa050. doi: 10.1093/ehjqcco/qcaa050. Online ahead of print.
38. Di Pasquale G, Maggioni AP. Studi clinici per la malattia COVID-19: navigando tra speranze e illusioni, in attesa di certezze. *G Ital Cardiol* 2020;21(7):479-482
39. Pessoa-Amorim G, Camm CF, Gajendragadkar P, De Maria GL, Arzac C, Laroche C, Zamorano JL, Weidinger F, Achenbach S, Maggioni AP, Gale CP, Poppas A, Casadei B. Admission of patients with STEMI since the outbreak of the COVID-19 pandemic. A survey by the European Society of Cardiology. *Eur Heart J Qual Care Clin Outcomes* 2020;6(3):210-216. doi: 10.1093/ehjqcco/qcaa046
40. Piccinni C, Dondi L, Ronconi G, Calabria S, Esposito I, Pedrini A, Maggioni AP, Barbui C, Martini N. Real-world data on new users of atypical antipsychotics: characterisation, prescription patterns,

- healthcare costs and early cardio-metabolic occurrences from a large Italian database. *Eur J Clin Pharmacol.* 2020 Sep;76(9):1301-1310. doi: 10.1007/s00228-020-02899-9.
41. Andreotti F, Maggioni AP. Lipoprotein(a) Reduction in Persons with Cardiovascular Disease. *N Engl J Med.* 2020 May 21;382(21):e65. doi: 10.1056/NEJMc2004861
42. Corrao G, Rea F, Carle F, et al. Measuring multimorbidity inequality across Italy through the multisource comorbidity score: a nationwide study [published online ahead of print, 2020 May 20]. *Eur J Public Health* 2020;30(5):916-921. doi: 10.1093/eurpub/ckaa063. [collaborators]
43. Magri D, Piepoli M, Corra U, Gallo G, Maruotti A, Vignati C, Salvioni E, Mapelli M, Paolillo S, Filardi PP, Girola D, Metra M, Scardovi AB, Lagioia R, Limongelli G, Senni M, Scutrinio D, Emdin M, Passino C, Lombardi C, Cattadori G, Parati G, Cicoira M, Correale M, Frigerio M, Clemenza F, Bussotti M, Guazzi M, Badagliacca R, Sciomer S, Lenarda AD, Maggioni A, Sinagra G, Volpe M, Agostoni P; MECKI score Research Group (see appendix). CARDIOVASCULAR DEATH RISK IN RECOVERED MID-RANGE EJECTION FRACTION HEART FAILURE: INSIGHTS FROM CARDIOPULMONARY EXERCISE TEST [published online ahead of print, 2020 May 16]. *J Card Fail.* 2020;S1071-9164(20)30031-2. doi:10.1016/j.cardfail.2020.04.021
44. Samuel M, Tardif JC, Khairy P, Roubille F, Waters DD, Gregoire JC, Pinto FJ, Maggioni AP, Diaz R, Berry C, Koenig W, Ostadal P, Lopez-Sendon J, Gamra H, Kiwan GS, Dube MP, Provencher M, Orfanos A, Blondeau L, Kouz S, L'Allier PL, Ibrahim R, Bouabdallaoui N, Mitchell D, Guertin MC, Leloir J. Cost-Effectiveness of Low-Dose Colchicine after Myocardial Infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT). *Eur Heart J Qual Care Clin Outcomes.* 2020 May 14;qcaa045. doi: 10.1093/ehjqcc/qcaa045. Epub ahead of print. PMID: 32407460.
45. Ameri P, Canepa M, Nicolosi GL, Marchioli R, Latini R, Tavazzi L, Maggioni AP; GISSI-HF. Cancer in chronic heart failure patients in the GISSI-HF trial. *Eur J Clin Invest* 2020;50:e13273. doi: 10.1111/eci.13273.
46. Lanfranconi S, Scola E, Bertani GA, Zarino B, Pallini R, d'Alessandris G, Mazzon E, Marino S, Carriero MR, Scelzo E, Farago G, Castori M, Fusco C, Petracca A, d'Agruma L, Tassi L, d'Orio P, Lampugnani MG, Nicolis EB, Vasami A, Novelli D, Torri V, Meessen JMTA, Salman RA, Dejana E, Latini R; Treat-CCM Investigators. Propranolol for familial cerebral cavernous malformation (Treat\_CCM): study protocol for a randomized controlled pilot trial. *Trials* 2020;21:401. doi: 10.1186/s13063-020-4202-x. [collaborators]
47. Ferrari R, Maggioni AP, Tavazzi L, Rapezzi C. The battle against COVID-19: mortality in Italy. *Eur Heart J.* 2020;41(22):2050-2052. doi: 10.1093/eurheartj/ehaa326.
48. Martini N, Piccinni C, Pedrini A, Maggioni A. [CoViD-19 and chronic diseases: current knowledge, future steps and the MaCroScopio project.] *Recenti Prog Med* 2020;111:198-201.
49. Maggioni A, Rapezzi C, Tavazzi L, Ferrari R. Key words to be adopted for COVID-19 research. *Eur Heart J.* 2020 Apr 15;ehaa322. doi: 10.1093/eurheartj/ehaa322. Online ahead of print.
50. Canepa M, Siri G, Puntoni M, Latini R, Tavazzi L, Maggioni AP. Testing longitudinal data for prognostication in ambulatory heart failure patients with reduced ejection fraction. A proof of principle from the GISSI-HF database. *Int J Cardiol* 2020;313:89-96. doi: 10.1016/j.ijcard.2020.03.064.
51. Andreotti F, Maggioni AP. Cancer unmasked by bleeding during anticoagulant therapy: when a problem may become an opportunity. *Eur Heart J.* 2020 Apr 8. pii: ehaa164. doi: 10.1093/eurheartj/ehaa164.
52. Rossignol P, Lainscak M, Crespo-Leiro MG, Laroche C, Piepoli MF, Filippatos G, Rosano GMC, Savarese G, Anker SD, Seferovic PM, Ruschitzka F, Coats AJS, Mebazaa A, McDonagh T, Sahuquillo A, Penco M, Maggioni AP, Lund LH; Heart Failure Long-Term Registry Investigators Group. Unravelling the interplay between hyperkalaemia, renin-angiotensin-aldosterone inhibitor use and clinical outcomes. Data from 9222 chronic heart failure patients of the ESC-HFA-EORP Heart Failure Long-Term Registry. *Eur J Heart Fail.* 2020 Apr 3. doi: 10.1002/ehf.1793. [Epub ahead of print]
53. Kapelios CJ, Laroche C, Crespo-Leiro MG, Anker SD, Coats AJS, Diaz-Molina B, Filippatos G, Lainscak M, Maggioni AP, McDonagh T, Mebazaa A, Metra M, Moura B, Mullens W, Piepoli MF, Rosano GMC, Ruschitzka F, Seferovic PM, Lund LH; Heart Failure Long-Term Registry Investigators Group. Association between loop diuretic dose changes and outcomes in chronic heart failure: observations from the ESC-EORP Heart Failure Long-Term Registry. *Eur J Heart Fail.* 2020 Apr 1. doi: 10.1002/ehf.1796. [Epub ahead of print]
54. Pozzoli M, Gonzalez-Costello J, Bayes-Genis A, Sinagra G, Anker SD, Coats AJS, Crespo-Leiro MG, Filippatos G, Laroche C, Maggioni AP, Mebazaa A, Piepoli MF, Tavazzi L; ESC Heart Failure Long-Term Registry Investigators Group. Prevalence of risk of thrombosis and of bleeding and antithrombotic treatment in patients with heart failure. *Eur J Heart Fail* 2020;22(5):906-910. doi:

10.1002/ejhf.1789.

55. Komajda M, Cosentino F, Ferrari R, Kerneis M, Kosmachova E, Laroche C, Maggioni AP, Rittger H, Steg PG, Szwed H, Tavazzi L, Valgimigli M, Gale CP; CICD investigators group. Profile and treatment of chronic coronary syndromes in European Society of Cardiology member countries: The ESC EORP CICD-LT registry. *Eur J Prev Cardiol.* 2020 Mar 31;2047487320912491. doi: 10.1177/2047487320912491. [Epub ahead of print] No abstract available.
56. Bangalore S, Maron DJ, O'Brien SM, Fleg JL, Kretov EI, Briguori C, Kaul U, Reynolds HR, Mazurek T, Sidhu MS, Berger JS, Mathew RO, Bockeria O, Broderick S, Pracon R, Herzog CA, Huang Z, Stone GW, Boden WE, Newman JD, Ali ZA, Mark DB, Spertus JA, Alexander KP, Chaitman BR, Chertow GM, Hochman JS; ISCHEMIA-CKD Research Group. Management of Coronary Disease in Patients with Advanced Kidney Disease. *N Engl J Med.* 2020 Apr 23;382(17):1608-1618. doi: 10.1056/NEJMoa1915925. Epub 2020 Mar 30.
57. Maron DJ, Hochman JS, Reynolds HR, Bangalore S, O'Brien SM, Boden WE, Chaitman BR, Senior R, Lopez-Sendon J, Alexander KP, Lopes RD, Shaw LJ, Berger JS, Newman JD, Sidhu MS, Goodman SG, Ruzyllo W, Gosselin G, Maggioni AP, White HD, Bhargava B, Min JK, Mancini GBJ, Berman DS, Picard MH, Kwong RY, Ali ZA, Mark DB, Spertus JA, Krishnan MN, Elghamaz A, Moorthy N, Hueb WA, Demkow M, Mavromatis K, Bockeria O, Peteiro J, Miller TD, Szwed H, Doerr R, Keltai M, Selvanayagam JB, Steg PG, Held C, Kohsaka S, Mavromichalis S, Kirby R, Jeffries NO, Harrell FE Jr, Rockhold FW, Broderick S, Ferguson TB Jr, Williams DO, Harrington RA, Stone GW, Rosenberg Y; ISCHEMIA Research Group. Initial Invasive or Conservative Strategy for Stable Coronary Disease. *N Engl J Med* 2020;382(15):1395-1407. doi: 10.1056/NEJMoa1915922.
58. Spertus JA, Jones PG, Maron DJ, Mark DB, O'Brien SM, Fleg JL, Reynolds HR, Stone GW, Sidhu MS, Chaitman BR, Chertow GM, Hochman JS, Bangalore S; ISCHEMIA-CKD Research Group. Health Status after Invasive or Conservative Care in Coronary and Advanced Kidney Disease. *N Engl J Med* 2020;382(17):1619-1628. doi: 10.1056/NEJMoa1916374. Epub 2020 Mar 30.
59. Davison BA, Takagi K, Senger S, Koch G, Metra M, Kimmoun A, Mebazaa A, Voors AA, Nielsen OW, Chioncel O, Pang PS, Greenberg BH, Maggioni AP, Cohen-Solal A, Ertl G, Sato N, Teerlink JR, Filippatos G, Ponikowski P, Gayat E, Edwards C, Cotter G. Mega-trials in heart failure: effects of dilution in examination of new therapies. *Eur J Heart Fail.* 2020 Mar 30. doi: 10.1002/ejhf.1780. [Epub ahead of print]
60. Bhatt DL, Eikelboom JW, Connolly SJ, Steg PG, Anand SS, Verma S, Branch KRH, Probstfield J, Bosch J, Shestakovska O, Szarek M, Maggioni AP, Widimsky P, Avezum A, Diaz R, Lewis BS, Berkowitz SD, Fox KAA, Ryden L, Yusuf S; COMPASS Steering Committee and Investigators. The Role of Combination Antiplatelet and Anticoagulation Therapy in Diabetes and Cardiovascular Disease: Insights from the COMPASS Trial. *Circulation* 2020;141(23):1841-1854. doi: 10.1161/CIRCULATIONAHA.120.046448.
61. Kramer F, Voss S, Roessig L, Igl BW, Butler J, Lam CSP, Maggioni AP, Shah SJ, Pieske B. Evaluation of high-sensitivity C-reactive protein and uric acid in vericiguat-treated patients with heart failure with reduced ejection fraction. *Eur J Heart Fail.* 2020 Mar 25. doi: 10.1002/ejhf.1787. [Epub ahead of print]
62. Shin SH, Claggett B, Pfeffer MA, Skali H, Liu J, Aguilar D, Diaz R, Dickstein K, Gerstein HC, Kober LV, Lawson FC, Lewis EF, Maggioni AP, McMurray JJV, Probstfield JL, Riddle MC, Tardif JC, Solomon SD; ELIXA Investigators. Hyperglycaemia, ejection fraction and the risk of heart failure or cardiovascular death in patients with type 2 diabetes and a recent acute coronary syndrome. *Eur J Heart Fail.* 2020 Jul;22(7):1133-1143. doi: 10.1002/ejhf.1790.
63. Kotseva K, De Backer G, De Bacquer D, Ryden L, Hoes A, Grobbee D, Maggioni A, Marques-Vidal P, Jennings C, Abreu A, Aguiar C, Badariene J, Bruthans J, Cifkova R, Davletov K, Dilic M, Dolzhenko M, Gaita D, Gotcheva N, Hasan-Ali H, Jankowski P, Lionis C, Mancas S, Milicic D, Mirrakhimov E, Oganov R, Pogossova N, Reiner Z, Vulic D, Wood D. Primary prevention efforts are poorly developed in people at high cardiovascular risk: A report from the European Society of Cardiology EURObservational Research Programme EUROASPIRE V survey in 16 European countries. *Eur J Prev Cardiol.* 2020 Mar 20;2047487320908698. doi: 10.1177/2047487320908698. [Epub ahead of print]
64. Motiejunaite J, Akiyama E, Cohen-Solal A, Maggioni AP, Mueller C, Choi DJ, Kavoliuniene A, Celutkiene J, Parenica J, Lassus J, Kajimoto K, Sato N, Miro O, Peacock WF, Matsue Y, Voors AA, Lam CSP, Ezekowitz JA, Ahmed A, Fonarow GC, Gayat E, Regitz-Zagrosek V, Mebazaa A. The association of long-term outcome and biological sex in patients with acute heart failure from different geographic regions. *Eur Heart J* 2020;41(13):1357-1364. doi: 10.1093/eurheartj/ehaa071.
65. Seferovic PM, Jankowska E, Coats AJS, Maggioni AP, Lopatin Y, Milinkovic I, Polovina M, Lainscak M, Timmis A, Huculeci R, Vardas P; Task Force of the HFA Atlas, and the ESC Atlas of

- Cardiology leadership, developed in collaboration with the National Heart Failure Societies of the ESC member and ESC affiliated member countries. The Heart Failure Association Atlas: rationale, objectives, and methods. *Eur J Heart Fail* 2020;22(4):638-645. doi: 10.1002/ejhf.1768.
66. Tardif JC, Dube MP, Pfeffer MA, Waters DD, Koenig W, Maggioni AP, McMurray JJV, Mooser V, White HD, Heinonen T, Black DM, Guertin MC; dal-GenE Investigators. Study design of Dal-GenE, a pharmacogenetic trial targeting reduction of cardiovascular events with dalcetrapib. *Am Heart J* 2020;222:157-165. doi: 10.1016/j.ahj.2020.01.007.
67. Ferrannini G, de Bacquer D, De Backer G, Kotseva K, Mellbin L, Wood D, Ryden L; EUROASPIRE V collaborators. Screening for Glucose Perturbations and Risk Factor Management in Dysglycemic Patients With Coronary Artery Disease-A Persistent Challenge in Need of Substantial Improvement: A Report From ESC EORP EUROASPIRE V. *Diabetes Care* 2020;43(4):726-733. doi: 10.2337/dc19-2165. [collaborators]
68. Bilchick KC, Wang Y, Curtis JP, Cheng A, Dharmarajan K, Shadman R, Dardas TF, Anand I, Lund LH, Dahlstrom U, Sartipy U, Maggioni A, O'Connor C, Levy WC. Modeling defibrillation benefit for survival among cardiac resynchronization therapy defibrillator recipients. *Am Heart J* 2020;222:93-104. doi: 10.1016/j.ahj.2019.12.017.
69. Zeymer U, Clark AL, Barrios V, Damy T, Drozd J, Fonseca C, Lund LH, Comite GD, Hupfer S, Maggioni AP. Management of heart failure with reduced ejection fraction in Europe: design of the ARIADNE registry. *ESC Heart Fail* 2020;7:727-736.
70. Bowman L, Baras A, Bombien R, Califf RM, Chen Z, Gale CP, Gaziano JM, Grobbee DE, Maggioni AP, Muse ED, Roden DM, Schroeder S, Wallentin L, Casadei B. Understanding the use of observational and randomized data in cardiovascular medicine. *Eur Heart J* 2020;41(27):2571-2578. doi: 10.1093/eurheartj/ehaa020.
71. Ferrannini G, Manca ML, Magnoni M, Andreotti F, Andreini D, Latini R, Maseri A, Maggioni AP, Ostroff RM, Williams SA, Ferrannini E. Coronary Artery Disease and Type 2 Diabetes: A Proteomic Study. *Diabetes Care*. 2020;43(4):843-851. doi: 10.2337/dc19-1902. Epub 2020 Jan 27.
72. Atlas Writing Group; ESC Atlas of Cardiology is a compendium of cardiovascular statistics compiled by the European Heart Agency, a department of the European Society of Cardiology; Developed in collaboration with the national societies of the European Society of Cardiology member countries, Timmis A, Townsend N, Gale CP, Torbica A, Lettino M, Petersen SE, Mossialos EA, Maggioni AP, Kazakiewicz D, May HT, De Smedt D, Flather M, Zuhlke L, Beltrame JF, Huculeci R, Tavazzi L, Hindricks G, Bax J, Casadei B, Achenbach S, Wright L, Vardas P. European Society of Cardiology: Cardiovascular Disease Statistics 2019 (Executive Summary). *Eur Heart J Qual Care Clin Outcomes* 2020;6:7-9.
73. Cemin R, Colivicchi F, Maggioni AP, Boriani G, De Luca L, Di Lenarda A, Di Pasquale G, Fabbri G, Lucci D, Gulizia MM; On the behalf of BLITZ-AF Investigators. One-year clinical events and management of patients with atrial fibrillation hospitalized in cardiology centers: Data from the BLITZ-AF study. *Eur J Intern Med*. 2020;74:55-60. doi: 10.1016/j.ejim.2019.12.006.
74. Maggioni AP, Dondi L, Andreotti F, Pedrini A, Calabria S, Ronconi G, Piccini C, Martini N. Four-year trends in oral anticoagulant use and declining rates of ischemic stroke among 194,030 atrial fibrillation patients drawn from a sample of 12 million people. *Am Heart J* 2020;220:12-19.
75. Timmis A, Townsend N, Gale CP, Torbica A, Lettino M, Petersen SE, Mossialos EA, Maggioni AP, Kazakiewicz D, May HT, de Smedt D, Flather M, Zuhlke L, Beltrame JF, Huculeci R, Tavazzi L, Hindricks G, Bax J, Casadei B, Achenbach S, Wright L, Vardas P; European Society of Cardiology. European Society of Cardiology: Cardiovascular Disease Statistics 2019. *Eur Heart J* 2020;41:12-85.
76. Comaschi M, Di Lenarda A, Medea G, Agliatoro A, Cucinotta D, Gulizia M, Vespasiani G, Zuin G, Nicolucci, Spandonaro F, Maggioni AP. INtegration of care for reaching targetS In Diabetic patiEnts: Design of the INSIDE Study. *Diabetes Ther* 2020;11(1):359-367.

#### Year 2019

1. Teerlink JR, Davison BA, Cotter G, Maggioni AP, Sato N, Chioncel O, Ertl G, Felker GM, Filippatos G, Greenberg BH, Pang PS, Ponikowski P, Edwards C, Senger S, Teichman SL, Nielsen OW, Voors AA, Metra M. Effects of serelaxin in patients admitted for acute heart failure: a meta-analysis. *Eur J Heart Fail* 2020;22(2):315-329. doi: 10.1002/ejhf.1692. Epub 2019 Dec 30.
2. Standl E, Stevens SR, Lohknygina Y, Bethel MA, Buse JB, Gustavson SM, Maggioni AP, Mentz RJ, Hernandez AF, Holman RR; EXSCEL Study Group. Confirming the Bidirectional Nature of the Association Between Severe Hypoglycemic and Cardiovascular Events in Type 2 Diabetes: Insights From EXSCEL. *Diabetes Care*. 2019 Dec 27. pii: dc191079. doi: 10.2337/dc19-1079. [Epub ahead of print]

3. Lainscak M, Milinkovic I, Polovina M, Crespo-Leiro MG, Lund LH, Anker SD, Laroche C, Ferrari R, Coats AJS, McDonagh T, Filippatos G, Maggioni AP, Piepoli MF, Rosano GMC, Ruschitzka F, Simic D, Asanin M, Eicher JC, Yilmaz MB, Seferovic PM; European Society of Cardiology Heart Failure Long-Term Registry Investigators Group. Sex- and age-related differences in the management and outcomes of chronic heart failure: an analysis of patients from the ESC HFA EORP Heart Failure Long-Term Registry. *Eur J Heart Fail*. 2019 Dec 20. doi: 10.1002/ejhf.1645. [Epub ahead of print]
4. Schmidt B, Brugada J, Arbelo E, Laroche C, Bayramova S, Bertini M, Letsas KP, Pison L, Romanov A, Scherr D, Tilz RR, Maggioni A, Adragao P, Lund J, Haman L, Oliveira MM, Dagnes N; AFA LT Investigators Group. Ablation strategies for different types of atrial fibrillation in Europe: results of the ESC-EORP EHRA Atrial Fibrillation Ablation Long-Term registry. *Europace*. 2019 Dec 10. pii: euz318. doi: 10.1093/europace/euz318. [Epub ahead of print]
5. Bonapace S, Rossi A, Laroche C, Crespo-Leiro MG, Piepoli MF, Coats AJS, Dahlstrom U, Malek F, Macarie C, Temporelli PL, Maggioni AP, Tavazzi L, and the European Society of Cardiology Heart Failure Long-Term Registry Investigators group. Brachial pulse pressure in acute heart failure. Results of the Heart Failure Registry. *ESC Heart Fail*. 2019 Dec 9. doi: 10.1002/ehf2.12537. [Epub ahead of print]
6. Piccinni C, Antonazzo IC, Maggioni AP, Pedrini A, Calabria S, Ronconi G, Dondi L, Martini N, Roberto G, Sampietro T, Sbrana F, Dal Pino B, Bigazzi F, Lo Surdo G, Volpi E, Biagini S, Gini R. PCSK9 Inhibitors' New Users: Analysis of Prescription Patterns and Patients' Characteristics from an Italian Real-world Study. *Clin Drug Investig*. 2019 Dec 3. doi: 10.1007/s40261-019-00877-3. [Epub ahead of print]
7. Rovai S, Corra U, Piepoli M, Vignati C, Salvioni E, Bonomi A, Mattavelli I, Arcari L, Scardovi AB, Perrone Filardi P, Lagioia R, Paolillo S, Magri D, Limongelli G, Metra M, Senni M, Scutunio D, Raimondo R, Emdin M, Lombardi C, Cattadori G, Parati G, Re F, Ciccoira M, Villani GQ, Mina C, Correale M, Frigerio M, Perna E, Mapelli M, Magini A, Clemenza F, Bussotti M, Battaia E, Guazzi M, Bandera F, Badagliacca R, Di Lenarda A, Pacileo G, Maggioni A, Passino C, Sciomer S, Sinagra G, Agostoni P; MECKI Score Research Group (see Appendix 1). Exercise oscillatory ventilation and prognosis in heart failure patients with reduced and mid-range ejection fraction. *Eur J Heart Fail*. 2019 Nov 28. doi: 10.1002/ejhf.1595. [Epub ahead of print]
8. Bethel MA, Mentz RJ, Merrill P, Buse JB, Chan JC, Goodman SG, Iqbal N, Jakuboniene N, Katona B, Lakhnygina Y, Lopes RD, Maggioni AP, Ohman P, Tankova T, Bakris GL, Hernandez AF, Holman RR. Microvascular and Cardiovascular Outcomes According to Renal Function in Patients Treated With Once-Weekly Exenatide: Insights From the EXSCEL Trial. *Diabetes Care*. 2019 Nov 22. pii: dc191065. doi: 10.2337/dc19-1065. [Epub ahead of print]
9. McMurray JJV, Jackson AM, Lam CSP, Redfield MM, Anand IS, Ge J, Lefkowitz MP, Maggioni AP, Martinez F, Packer M, Pfeffer MA, Pieske B, Rizkala AR, Sabarwal SV, Shah AM, Shah SJ, Shi VC, van Veldhuisen DJ, Zannad F, Zile MR, Cikes M, Goncalvesova E, Katova T, Kosztin A, Lelonek M, Sweitzer NK, Vardeny O, Claggett B, Jhund PS, Solomon SD. Effects of Sacubitril-Valsartan, versus Valsartan, in Women Compared to Men with Heart Failure and Preserved Ejection Fraction: Insights from PARAGON-HF. *Circulation*. 2019 Nov 17. doi: 10.1161/CIRCULATIONAHA.119.044491. [Epub ahead of print]
10. Tardif JC, Kouz S, Waters DD, Bertrand OF, Diaz R, Maggioni AP, Pinto FJ, Ibrahim R, Gamra H, Kiwan GS, Berry C, Lopez-Sendon J, Ostadal P, Koenig W, Angoulvant D, Gregoire JC, Lavoie MA, Dube MP, Rhoads D, Provencher M, Blondeau L, Orfanos A, L'Allier PL, Guertin MC, Roubille F. Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction. *N Engl J Med* 2019;381:2497-2505.
11. Savonitto S, De Servi S, Maggioni AP, Cesana BM. Interruzione anticipata delle sperimentazioni cliniche: rationale e interpretazione. *G Ital Cardiol (Rome)* 2019;20(11):619-626.
12. Balabanski T, Brugada J, Arbelo E, Laroche C, Maggioni A, Blomstrom-Lundqvist C, Kautzner J, Tavazzi L, Tritto M, Kulakowski P, Kalejs O, Forster T, Villalobos FS, Dagnes N; ESC-EHRA Atrial Fibrillation Ablation Long-Term Registry investigators Group. Impact of monitoring on detection of arrhythmia recurrences in the ESC-EHRA EORP atrial fibrillation ablation long-term registry. *Europace*. 2019 Aug 13. pii: euz216. doi: 10.1093/europace/euz216. [Epub ahead of print]
13. Crespo-Leiro MG, Barge-Caballero E, Segovia-Cubero J, Gonzalez-Costello J, Lopez-Fernandez S, Garcia-Pinilla JM, Almenar-Bonet L, de Juan-Baguda J, Roig-Minguell E, Bayes-Genis A, Sanz-Julve M, Lambert-Rodriguez JL, Lara-Padron A, Perez-Ruiz JM, Fernandez-Vivancos Marquina C, de la Fuente-Galan L, Varela-Roman A, Torres-Calvo F, Andres-Novales J, Escudero-Gonzalez A, Pascual-Figal DA, Ridocci-Soriano F, Sahuquillo-Martinez A, Bierge-Valero D, Epelde-Gonzalo F, Gallego-Page JC, Dalmau Gonzalez-Gallarza R, Bover-Freire R, Quiles-Granado J, Maggioni AP, Lund LH, Muniz J, Delgado-Jimenez J.

- Hyperkalemia in heart failure patients in Spain and its impact on guidelines and recommendations: ESC-EORP-HFA Heart Failure Long-Term Registry. *Rev Esp Cardiol (Engl Ed)* 2020; 73:313-323.
14. Polewczyk A, Rinaldi CA, Sohal M, Golzio PG, Claridge S, Cano O, Laroche C, Kennergren C, Deharo JC, Kutarski A, Butter C, Blomstrom-Lundqvist C, Romano SL, Maggioni AP, Auricchio A, Diemberger I, Pisano ECL, Rossillo A, Kuck KH, Forster T, Bongioni MG; ELECTRa investigators group. Transvenous lead extraction procedures in women based on ESC-EHRA EORP European Lead Extraction ConTrolled ELECTRa registry: is female sex a predictor of complications? *Europace*. 2019 Oct 30. pii: euz277. doi: 10.1093/europace/euz277. [Epub ahead of print]
  15. Nof E, Bongioni MG, Auricchio A, Butter C, Dagnes N, Deharo JC, Rinaldi CA, Maggioni AP, Kutarski A, Kennergren C, Laroche C, Milman A, Beinart R, Bogdan S, Mortsell D, Calvi V, Desiron Q, Mansourati J, Lundqvist CB, Glikson M. Comparison of outcomes in infected cardiovascular implantable electronic devices between complete, partial, and failed lead removal: an ESC-EHRA-EORP ELECTRa (European Lead Extraction ConTrolled) registry. *Europace*. 2019 Oct 18. pii: euz269. doi: 10.1093/europace/euz269. [Epub ahead of print]
  16. Lettino M, Maggioni AP. [Conclusions]. *G Ital Cardiol (Rome)*. 2019 Oct;20(10 Suppl. 2):24-25.
  17. Lettino M, Maggioni AP. [Introduction]. *G Ital Cardiol (Rome)*. 2019 Oct;20(10 Suppl. 2):3.
  18. Vanassche T, Verhamme P, Anand SS, Shestakovska O, Fox KA, Bhatt DL, Avezum A, Alings M, Aboyans V, Maggioni AP, Widimsky P, Berkowitz SD, Yusuf S, Connolly SJ, Eikelboom JW, Bosch J. Risk factors and clinical outcomes in chronic coronary and peripheral artery disease: An analysis of the randomized, double-blind COMPASS trial. *Eur J Prev Cardiol*. 2019 Oct 15:2047487319882154. doi: 10.1177/2047487319882154. [Epub ahead of print]
  19. Komajda M, Cosentino F, Ferrari R, Laroche C, Maggioni A, Steg PG, Tavazzi L, Kerneis M, Valgimigli M, Gale CP; CICD investigators group. Cohort profile The ESC-EORP Chronic Ischemic Cardiovascular Disease Long-Term (CICD LT) registry. *Eur Heart J Qual Care Clin Outcomes*. 2019 Oct 11. pii: qcz057. doi: 10.1093/ehjqcc/qcz057. [Epub ahead of print]
  20. Eikelboom JW, Bosch JJ, Connolly SJ, Shestakovska O, Dagenais GR, Hart RG, Leong DP, O'Donnell M, Fox KAA, Bhatt DL, Cairns JA, Tasto C, Berkowitz SD, Cook Bruns N, Muehlhofer E, Diaz R, Maggioni AP, Yusuf S. Major Bleeding in Patients With Coronary or Peripheral Artery Disease Treated With Rivaroxaban Plus Aspirin. *J Am Coll Cardiol* 2019;74:1519-1528
  21. Lung B, Delgado V, Rosenhek R, Price S, Prendergast B, Wendler O, De Bonis M, Tribouilloy C, Evangelista A, Bogachev-Prokophiev A, Apor A, Ince H, Laroche C, Popescu BA, Pierard L, Haude M, Hindricks G, Ruschitzka F, Windecker S, Bax JJ, Maggioni A, Vahanian A; EORP VHD II Investigators. Contemporary Presentation and Management of Valvular Heart Disease: The EURObservational Research Programme Valvular Heart Disease II Survey. *Circulation*. 2019 Sep 12. doi: 10.1161/CIRCULATIONAHA.119.041080. [Epub ahead of print]
  22. Matthews DR, Paldanius PM, Proot P, Chiang Y, Stumvoll M, Del Prato S; VERIFY study group. Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, double-blind trial. *Lancet*. 2019 Sep 17. pii: S0140-6736(19)32131-2. doi: 10.1016/S0140-6736(19)32131-2. [acknowledgement]
  23. Eikelboom JW, Connolly SJ, Bosch J, Shestakovska O, Aboyans V, Alings M, Anand SS, Avezum A, Berkowitz SD, Bhatt DL, Cook Bruns N, Felix C, Fox KAA, Hart RG, Maggioni AP, Moayyedi P, O'Donnell M, Ryden L, Verhamme P, Widimsky P, Zhu J, Yusuf S; COMPASS investigators. Bleeding and New Cancer Diagnosis in Patients with Atherosclerosis. *Circulation* 2019;140:1451-1459.
  24. Wallentin L, Gale CP, Maggioni A, Bardinet I, Casadei B. EuroHeart: European Unified Registries On Heart Care Evaluation and Randomized Trials. *Eur Heart J* 2019; 40:2745-2759.
  25. Habib G, Erba PA, Lung B, Donal E, Cosyns B, Laroche C, Popescu BA, Prendergast B, Tornos P, Sadeghpour A, Oliver L, Vaskelyte JJ, Sow R, Axler O, Maggioni AP, Lancellotti P. Clinical presentation, aetiology and outcome of infective endocarditis. Results of the ESC-EORP EURO-ENDO (European infective endocarditis) registry: a prospective cohort study. *Eur Heart J* 2019;40:3222-3232.
  26. Solomon SD, McMurray JJV, Anand IS, Ge J, Lam CSP, Maggioni AP, Martinez F, Packer M, Pfeffer MA, Pieske B, Redfield MM, Rouleau JL, van Veldhuisen DJ, Zannad F, Zile MR, Desai AS, Claggett B, Jhund PS, Boytsov SA, Comin-Colet J, Cleland J, Dungen HD, Goncalvesova E, Katova T, Kerr Saraiva JF, Lelonek M, Merkely B, Senni M, Shah SJ, Zhou J, Rizkala AR, Gong J, Shi VC, Lefkowitz MP; PARAGON-HF Investigators and Committees. Angiotensin-Nepriylsin Inhibition in Heart Failure with Preserved Ejection Fraction. *N Engl J Med* 2019;381:1609-1620.
  27. Andreini D, Magnoni M, Conte E, Masson S, Mushtaq S, Berti S, Canestrari M, Casolo G, Gabrielli D, Latini R, Marraccini P, Moccetti T, Modena MG, Pontone G, Gorini M, Maggioni AP,

- Maseri A; CAPIRE Investigators. Coronary Plaque Features on CTA Can Identify Patients at Increased Risk of Cardiovascular Events. *JACC Cardiovasc Imaging*. 2019 Aug 8. pii: S1936-878X(19)30611-4. doi: 10.1016/j.jcmg.2019.06.019. [Epub ahead of print]
28. Giorda CB, Cioffi G, Lucci D, Nada E, Ognibeni F, Mancusi C, Latini R, Maggioni AP; DYDA 2 Investigators. Effects of Dipeptidyl Peptidase-4 Inhibitor Linagliptin on Left Ventricular Dysfunction in Patients with Type 2 Diabetes and Concentric Left Ventricular Geometry (the DYDA 2 Trial). Rationale, Design, and Baseline Characteristics of the Study Population. *Cardiovasc Drugs Ther*. 2019 Aug 15. doi: 10.1007/s10557-019-06898-6. [Epub ahead of print]
29. Trines SA, Stabile G, Arbelo E, Dagres N, Brugada J, Kautzner J, Pokushalov E, Maggioni AP, Laroche C, Anselmino M, Beinart R, Traykov V, Lundqvist CB; ESC-EHRA Atrial Fibrillation Ablation Long-Term Registry investigators. Influence of risk factors in the ESC-EHRA EORP atrial fibrillation ablation long-term registry. *Pacing Clin Electrophysiol* 2019;42:1365-1373.
30. Maggioni AP, Andreotti F. Stroke prevention by low-dose anticoagulation in patients with heart failure and sinus rhythm: is it worth the effort? *Eur Heart J* 2019;40:3602-3604.
31. Hallen J, Maggioni AP, Lopez-de-Sa E, Turazza FM, Witte K, Erdmann E, Dahlstrom U, Ertl G, Nielsen OW, Lopez Sendon J, Holbro T, Chen CW, Gimpelewicz C, Cowie MR. Reproducibility of in-hospital worsening heart failure event adjudication in the RELAX-AHF-EU trial. *Eur J Heart Fail*. 2019 Jul 29. doi: 10.1002/ejhf.1574.
32. Maggioni AP. Omega-3 Fatty Acids and Heart Failure: Evidence and Still Open Questions. *JACC Heart Fail* 2019;7:662-663.
33. Chandra A, Vaduganathan M, Lewis EF, Claggett BL, Rizkala AR, Wang W, Lefkowitz MP, Shi VC, Anand IS, Ge J, Lam CSP, Maggioni AP, Martinez F, Packer M, Pfeffer MA, Pieske B, Redfield MM, Rouleau JL, Van Veldhuisen DJ, Zannad F, Zile MR, McMurray JJV, Solomon SD; PARAGON-HF Investigators. Health-Related Quality of Life in Heart Failure With Preserved Ejection Fraction: The PARAGON-HF Trial. *JACC Heart Fail* 2019;7:862-874.
34. Branch KR, Probstfield JL, Eikelboom JW, Bosch J, Maggioni AP, Cheng RK, Bhatt DL, Avezum A, Fox KAA, Connolly SJ, Shestakovska O, Yusuf S. Rivaroxaban With or Without Aspirin in Patients with Heart Failure and Chronic Coronary or Peripheral Artery Disease: The COMPASS Trial. *Circulation* 2019;140:529-537.
35. Moayyedi P, Eikelboom JW, Bosch J, Connolly SJ, Dyal L, Shestakovska O, Leong D, Anand SS, Stork S, Branch KRH, Bhatt DL, Verhamme PB, O'Donnell M, Maggioni AP, Lonn EM, Piegas LS, Ertl G, Keltai M, Bruns NC, Muehlhofer E, Dagenais GR, Kim JH, Hori M, Steg PG, Hart RG, Diaz R, Alings M, Widimsky P, Avezum A, Probstfield J, Zhu J, Liang Y, Lopez-Jaramillo P, Kakkar AK, Parkhomenko AN, Ryden L, Pogosova N, Dans AL, Lanas F, Commerford PJ, Torp-Pedersen C, Guzik TJ, Vinereanu D, Tonkin AM, Lewis BS, Felix C, Yusoff K, Metsarinne KP, Fox KAA, Yusuf S; COMPASS Investigators. Safety of Proton Pump Inhibitors Based on a Large, Multi-Year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin. *Gastroenterology* 2019;157:682-691.e2.
36. Kapelios CJ, Lainscak M, Savarese G, Laroche C, Seferovic P, Ruschitzka F, Coats A, Anker SD, Crespo-Leiro MG, Filippatos G, Piepoli MF, Rosano G, Zanolla L, Aguiar C, Murin J, Leszek P, McDonagh T, Maggioni AP, Lund LH; HF LT Registry Investigators group. Sacubitril/valsartan eligibility and outcomes in the ESC HFA EORP Heart Failure Long-Term Registry: bridging between EMA/FDA label, the PARADIGM-HF trial, ESC Guidelines, and real-world. *Eur J Heart Fail* 2019;21:1383-1397.
37. Chioncel O, Mebazaa A, Maggioni AP, Harjola VP, Rosano G, Laroche C, Piepoli MF, Crespo-Leiro MG, Lainscak M, Ponikowski P, Filippatos G, Ruschitzka F, Seferovic P, Coats AJS, Lund LH; ESC-EORP HFA Heart Failure Long-Term Registry Investigators. Acute heart failure congestion and perfusion status - impact of the clinical classification on in-hospital and long-term outcomes; insights from the ESC-EORP-HFA Heart Failure Long-Term Registry. *Eur J Heart Fail* 2019;21:1338-1352.
38. Maggioni AP. Appropriate prescriptions mean better outcomes: how can we improve ourselves? *Eur J Heart Fail* 2019; 21:930-931.
39. Piccinni C, Calabria S, Ronconi G, Dondi L, Pedrini A, Esposito I, Marangolo M, Maggioni AP, Martini N. [Facts and figures of clinical pathways in Italy: results from the PDTA Net project.] *Recenti Prog Med* 2019;110(4):188-194.
40. Di Cori A, Auricchio A, Regoli F, Blomstrom-Lundqvist C, Butter C, Dagres N, Deharo JC, Maggioni AP, Kutarski A, Kennergren C, Laroche C, Rinaldi CA, Dovellini EV, Golzio PG, Thogersen AM, Bongiorno MG; ESC-EHRA ELECTRa Investigators. Clinical impact of antithrombotic therapy in transvenous lead extraction complications: a sub-analysis from the ESC-EORP EHRA ELECTRa (European Lead Extraction ConTRolled) Registry. *Europace* 2019;21:1096-1105. doi:

41. Vaccaro O, Lucisano G, Masulli M, Bonora E, Del Prato S, Rivellese AA, Giorda CB, Mocarelli P, Squatrito S, Maggioni AP, Riccardi G, Nicolucci A; TOSCA.IT investigators. Cardiovascular effects of pioglitazone or sulphonylureas according to pretreatment risk: moving towards personalized care. *J Clin Endocrinol Metab.* 2019 Aug 1;104(8):3296-3302.
42. Zeymer U, Ludman P, Danchin N, Kala P, Maggioni AP, Weidinger F. THE ESC ACCA EAPCI EORP Acute Coronary Syndrome ST elevation myocardial infarction (ACS STEMI) REGISTRY. *Eur Heart J Qual Care Clin Outcomes* 2020;6:100-104.
43. Moayyedi P, Eikelboom JW, Bosch J, Connolly SJ, Dyal L, Shestakovska O, Leong D, Anand SS, Stork S, Branch KRH, Bhatt DL, Verhamme PB, O'Donnell M, Maggioni AP, Lonn EM, Piegas LS, Ertl G, Keltai M, Bruns NC, Muehlhofer E, Dagenais GR, Kim JH, Hori M, Steg PG, Hart RG, Diaz R, Alings M, Widimsky P, Avezum A, Probstfield J, Zhu J, Liang Y, Lopez-Jaramillo P, Kakkar A, Parkhomenko A, Ryden L, Pogosova N, Dans A, Lanas F, Commerford PJ, Torp-Pedersen C, Guzik T, Vinereanu D, Tonkin AM, Lewis BS, Felix C, Yusoff K, Metsarinne K, Fox KAA, Yusuf S; COMPASS investigators. Pantoprazole to Prevents Gastrointestinal Events in Patients Receiving Rivaroxaban and/or Aspirin in a Randomized, Double-blind, Placebo-controlled Trial. *Gastroenterology* 2019;157:403-412.e5.
44. De Backer G, Jankowski P, Kotseva K, Mirrakhimov E, Reiner Z, Ryden L, Tokgozoglul L, Wood D, De Bacquer D; EUROASPIRE V collaborators; Writing Committee; Scientific Steering/ Executive Committee; Coordinating centre; Diabetes centre; Data management centre; Statistical analysis centre; Central laboratory; Study centres, organisations, investigators and other research personnel (National Co-ordinators in each country are indicated by asterisk. Management of dyslipidaemia in patients with coronary heart disease: Results from the ESC-EORP EUROASPIRE V survey in 27 countries. *Atherosclerosis* 2019;285:135-146.
45. Arca M, Canonico PL, Colivicchi F, Favaretti C, Perrone Filardi P, Maggioni AP. L'importanza degli inibitori della PCSK9 nella prevenzione secondaria di eventi cardiovascolari in pazienti con malattia aterosclerotica: un'analisi GRADE dello studio Fourier per l'evolucumab. In: *Clinico Economics*. Anno 2019/Supplemento 1. SAVE, Milano.
46. Habib G, Lancellotti P, Erba PA, Sadeghpour A, Meshaal M, Sambola A, Furnaz S, Citro R, Ternacle J, Donal E, Cosyns B, Popescu B, Lung B, Prendergast B, Laroche C, Tornos P, Pazdernik M, Maggioni A, Gale CP; EURO-ENDO Investigators. The ESC-EORP EURO-ENDO (European Infective Endocarditis) registry. *Eur Heart J Qual Care Clin Outcomes* 2019;5:202-207.
47. Roos-Hesselink J, Baris L, Johnson M, De Backer J, Otto C, Marelli A, Jondeau G, Budts W, Grewal J, Sliwa K, Parsonage W, Maggioni AP, van Hagen I, Vahanian A, Tavazzi L, Elkayam U, Boersma E, Hall R. Pregnancy outcomes in women with cardiovascular disease: evolving trends over 10 years in the ESC Registry Of Pregnancy And Cardiac disease (ROPAC). *Eur Heart J.* 2019 Mar 25. pii: ehz136. doi: 10.1093/eurheartj/ehz136. [Epub ahead of print]
48. Boriani G, Proietti M, Laroche C, Fauchier L, Marin F, Nabauer M, Potpara T, Dan GA, Kalarus Z, Tavazzi L, Maggioni AP, Lip GYH; EORP-AF Long-Term General Registry Investigators. Association between antithrombotic treatment and outcomes at 1-year follow-up in patients with atrial fibrillation: the EORP-AF General Long-Term Registry. *Europace* 2019;21:1013-1022.
49. SPS I supplementi di Politiche sanitarie. Concept paper sul Progetto inibitori di PCSK9: accesso e sostenibilita. *Pensiero Scientifico Editore*. SPS n. 1, 2019.
50. Hochman JS, Reynolds HR, Bangalore S, O'Brien SM, Alexander KP, Senior R, Boden WE, Stone GW, Goodman SG, Lopes RD, Lopez-Sendon J, White HD, Maggioni AP, Shaw LJ, Min JK, Picard MH, Berman DS, Chaitman BR, Mark DB, Spertus JA, Cyr DD, Bhargava B, Ruzyllo W, Wander GS, Chernyavskiy AM, Rosenberg YD, Maron DJ; ISCHEMIA Research Group. Baseline Characteristics and Risk Profiles of Participants in the ISCHEMIA Randomized Clinical Trial. *JAMA Cardiol* 2019;4:273-286.
51. Kotseva K, De Backer G, De Bacquer D, Ryden L, Hoes A, Grobbee D, Maggioni A, Marques-Vidal P, Jennings C, Abreu A, Aguiar C, Badariene J, Bruthans J, Castro Conde A, Cifkova R, Crowley J, Davletov K, Deckers J, De Smedt D, De Sutter J, Dilic M, Dolzhenko M, Dzerve V, Erglis A, Fras Z, Gaita D, Gotcheva N, Heuschmann P, Hasan-Ali H, Jankowski P, Lalic N, Lehto S, Lovic D, Mancas S, Mellbin L, Milicic D, Mirrakhimov E, Oganov R, Pogosova N, Reiner Z, Stoerk S, Tokgozoglul L, Tsioufous C, Vulic D, Wood D; EUROASPIRE Investigators\*. Lifestyle and impact on cardiovascular risk factor control in coronary patients across 27 countries: Results from the European Society of Cardiology ESC-EORP EUROASPIRE V registry. *Eur J Prev Cardiol* 2019;26:824-835.
52. Cholesterol Treatment Trialists' Collaboration. Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials. *Lancet*



2019;393:407-415. (collaborators)

53. Sharma M, Hart RG, Connolly SJ, Bosch J, Shestakovska O, Ng KKH, Catanese L, Keltai K, Aboyans V, Alings M, Ha JW, Varigos J, Tonkin A, O'Donnell M, Bhatt DL, Fox K, Maggioni A, Berkowitz SD, Cook Bruns N, Yusuf S, Eikelboom JW. Stroke Outcomes in COMPASS Trial. *Circulation* 2019;139:1134-1145.
54. Ozieranski K, Balsam P, Kaplon-Cieslicka A, Tyminska A, Kowalik R, Grabowski M, Peller M, Wanczer A, Marchel M, Crespo-Leiro MG, Maggioni AP, Drozd J, Filipiak KJ, Opolski G. Comparative Analysis of Long-Term Outcomes of Torasemide and Furosemide in Heart Failure Patients in Heart Failure Registries of the European Society of Cardiology. *Cardiovasc Drugs Ther* 2019;33:77-86.
55. Balsam P, Ozieranski K, Kaplon-Cieslicka A, Borodzicz S, Tyminska A, Peller M, Marchel M, Crespo-Leiro MG, Maggioni AP, Drozd J, Opolski G, Grabowski M. Differences in clinical characteristics and one-year outcomes of hospitalized heart failure patients in succeeding European Society of Cardiology-Heart Failure Registries - Pilot and Long-Term. *Pol Arch Intern Med* 2019;129:106-116.
56. Antonini L, Mollica C, Aspromonte N, Pasceri V, Auriti A, Gonzini L, Maggioni P, Colivicchi F. A simple prognostic index in acute heart failure. *Minerva Cardioangiol* 2019;67:73-78.
57. Paolillo S, Veglia F, Salvioni E, Corra U, Piepoli M, Lagioia R, Limongelli G, Sinagra G, Cattadori G, Scardovi AB, Metra M, Senni M, Bonomi A, Scrutinio D, Raimondo R, Emdin M, Magri D, Parati G, Re F, Cicoira M, Mina C, Correale M, Frigerio M, Bussotti M, Battaia E, Guazzi M, Badagliacca R, Di Lenarda A, Maggioni A, Passino C, Sciomer S, Pacileo G, Mapelli M, Vignati C, Clemenza F, Binno S, Lombardi C, Filardi PP, Agostoni P; MECKI Score Research Group (see Appendix). Heart failure prognosis over time: how the prognostic role of oxygen consumption and ventilatory efficiency during exercise has changed in the last 20 years. *Eur J Heart Fail* 2019;21:208-217.
58. Stabile G, Trines SA, Arbelo E, Dagres N, Brugada J, Kautzner J, Pokushalov E, Maggioni AP, Laroche C, Anselmino M, Beinart R, Traykov V, Blomstrom Lundqvist C; ESC-EHRA Atrial Fibrillation Ablation Long-Term Registry investigators. Atrial fibrillation history impact on catheter ablation outcome. Findings from the ESC-EHRA atrial fibrillation ablation long term registry. *Pacing Clin Electrophysiol* 2019;42:313-320.
59. Maggioni AP. Where are we with the Eurobservational Research Programme in 2018? *Dialogues Cardiovasc Med.* 2019;24(#1):76-80
60. Segreti L, Rinaldi CA, Claridge S, Svendsen JH, Blomstrom-Lundqvist C, Auricchio A, Butter C, Dagres N, Deharo JC, Maggioni AP, Kutarski A, Kennergren C, Laroche C, Kempa M, Magnani A, Casteigt B, Bongiorni MG. Procedural outcomes associated with transvenous lead extraction in patients with abandoned leads: an ESC-EHRA ELECTRa (European Lead Extraction ConTRolled) Registry Sub-Analysis. *Europace* 2019;21:645-654.
61. Maggioni AP, Lopez-Sendon J, Nielsen OW, Hallen J, Aalamian-Mattheis M, Wang Y, Ertl G. Efficacy and safety of serelaxin when added to the standard of care in patients with acute heart failure: Results from a PROBE study, RELAX-AHF-EU. *Eur J Heart Fail* 2019;21:322-333.

## Projects Participation in Clinical Studies

The main activities in the last 20 years have been focused on the conduction of clinical trials and surveys/registries in the field of:

- Cardiology: acute coronary syndromes, cardiovascular prevention, arrhythmias, acute and chronic heart failure
- Cerebrovascular diseases
- Renal diseases
- Endocrinology: diabetes, obesity

The list of trials and the description of the responsibility in their conduction is reported below. The active participation in these large number of epidemiological and controlled studies provided a deep knowledge and expertise in clinical trial methodology.

Arrhythmias

ADEG (member of the Steering Committee)

GISSI-AF (member of the Steering Committee)

ACTIVE (member of the Clinical Events Evaluation Committee)

ARISTOTLE (member of the Safety and Data Monitoring Board)

SYNCRIA (member of the Safety and Data Monitoring Board)

OPERA (member of the Clinical Events Evaluation Committee)

Heart Failure  
RESOLVD Pilot Study (co-chairman of the study)  
SPICE Study (member of the Steering Committee)  
IN-CHF Registry (member of the Steering Committee and Study Coordinator)  
SEOSI Study (member of the Steering Committee)  
Val-HeFT Trial (deputy member of the Steering Committee)  
BRING-UP Trial (member of the Steering Committee and Study Coordinator)  
CHARM Trial (member of the Steering Committee)  
OVERTURE (member of the Steering Committee)  
GISSI-HF (member of the Steering Committee)  
EVEREST (member of the Steering/Executive Committee)  
RED-HF (member of the Steering/Executive Committee)  
RENO DEFEND (member of the Steering/Executive Committee)  
ATMOSPHERE (National Coordinator)  
ASTRONAUT (co-chairman of the Steering/Executive Committee)  
COMPOSE (member of the Steering Committee)  
ARTS (chairman of the Safety and Data Monitoring Board)  
ESC HF-Pilot (chairman of the Steering/Executive Committee)  
ESC HF Long-Term Registry (chairman of the Steering/Executive Committee)  
RESHAPE-HF (member of the Steering/Executive Committee)  
TRUE-HF (member of the Steering/Executive Committee)  
SOCRATES (member of the Steering/Executive Committee)  
PARAGON (member of the Steering/Executive Committee)  
ARTS-2 (member of the Steering/Executive Committee)  
RELAX-AHF-EU (chairman of the Steering/Executive Committee)  
ARIADNE (chairman of the Steering/Executive Committee)  
PURE HF (member of the Safety and Data Monitoring Board)  
Cardiovascular Prevention  
GISSI-Prevenzione (member of the Coordinating Center)  
PEACE (member of the Steering and of the Clinical Events Evaluation Committee)  
RUTH (member of the Clinical Events Evaluation Committee)  
NAVIGATOR (member of the Safety and Data Monitoring Board)  
ONTARGET/TRANSCEND (member of the Steering Committee, member of the Clinical Events Evaluation Committee)  
SIGNIFY (member of the Safety and Data Monitoring Board)  
Dal-OUTCOME (National Coordinator)  
CARDYOSIS (member of the Steering Committee)  
ISCHEMIA (member of the Steering Committee)  
REVEAL-HPS3 (member of the Steering Committee)  
COMPASS (member of the Steering Committee)  
Diabetes/obesity  
ORIGIN (member of the Steering Committee)  
SCOUT (member of the Steering/Executive Committee)  
TIDE (member of the Steering Committee)  
ELIXA (member of the Executive and of the Steering Committee)  
EXSCEL (member of the Executive and of the Steering Committee)  
FIDELIO-DKD (chairman of the Data Monitoring Committee)  
FIGARO-DKD (chairman of the Data Monitoring Committee)  
Pulmonary hypertension  
COMPASS II (member of the Safety and Data Monitoring Board)  
Myocardial infarction  
GISSI-1 (member of the Clinical Events Evaluation Committee)

GISSI-2 (member of the Coordinating Center)  
 GISSI-3 (member of the Coordinating Center)  
 GISSI-EFRIM (member of the Steering Committee)  
 GISSI Nursing (member of the Steering Committee)  
 GISSI-Prognosis (member of the Steering Committee)  
 ISIS-3 (member of the Steering Committee)  
 ISIS-4 (member of the Steering Committee)  
 ECLA-3 (member of the Scientific Committee)  
 CORE (member of the Steering Committee)  
 OAT (member of the Steering Committee)  
 LATIN (member of the Executive Committee and Study Coordinator)  
 MISTRAL (member of the Executive Committee and Study Coordinator)  
 ASSENT-2 (member of the Safety and Data Monitoring Board)  
 ASSENT-3 (member of the Safety and Data Monitoring Board)  
 ASSENT-3 Plus (member of the Safety and Data Monitoring Board)  
 ASSENT-4 (member of the Safety and Data Monitoring Board)  
 VALIANT (member of the Executive and of the Steering Committee)  
 BEAUTIFUL (member of the Steering Committee, as National Leader)  
 BLITZ 1 (member of the Executive Committee)  
 APPRAISE 2 (member of the Safety and Data Monitoring Board)  
 PARADISE (member of the Executive and of the Steering Committee)  
 CHIARA MIA (chairman of the Data Monitoring Committee)  
 Renal diseases  
 ARI (member of the Steering Committee)  
 ALTITUDE (National Coordinator)  
 Stroke  
 MAST (member of the Clinical Events Evaluation Committee)  
 Unstable angina/NSTEMI  
 OASIS-2 (member of the Steering Committee)  
 CURE (member of the Steering Committee)  
 EMAI (member of the Steering Committee)  
 CURRENT (member of the Steering Committee)  
 APPRAISE 2 (member of the Safety and Data Monitoring Board)  
 BLITZ 2 (member of the Executive Committee)

#### Memberships

##### Scientific and Academic experience

1996 to 2007: Associate Editor of the following Journal: Evidence-Based Cardiovascular Medicine.  
 1996 to date: Associate Editor of the following Journal: Italian Journal of Cardiology (now Journal of Cardiovascular Medicine)  
 2000 to date: Editorial Board of: European Heart Journal; Cardiovascular Drugs and Therapy; European Heart Journal of Heart Failure  
 2002 to 2009: National Coordinator of the Euro Heart Surveys  
 2005 to 2009: Contract Professor of Methodology of Clinical Research at the University of Bologna  
 2007 to date: Contract Professor of the Master on Epidemiology and Methodology of Clinical Research at the Univ. of Ferrara  
 2008 to 2010: Member of the Board of the Association on Heart Failure of the European Society of Cardiology  
 2010 to date: General Secretary of the Board of the Association on Heart Failure of the European Society of Cardiology  
 2008 to 2013: Editorial Board of: Circulation Cardiovascular Quality and Outcomes; BMJ Clinical cases  
 2009 to date: Scientific Coordinator of the EURObservational Research Program of the European Society of Cardiology

2010 to date: Guest Editor of Circulation

2015: included in the list of highly cited researchers over the last 11 years (2003-2013) by Thomson Reuters

2016: included in the list of highly cited researchers for year 2015 by Thomson Reuters

2016 to date: Associate Editor of the International Journal of Cardiology

2020 to date: Editorial Board Member to Global and Regional Health Technology Assessment (GRHTA)

2017-2019 included in the list of highly cited researchers by Clarivate

2021 to date: Editorial Board Member of The Romanian Journal of Cardiology

2021 to date: Editorial Board Member of Journal of Clinical Medicine

#### Experience in Regulatory activities

2002 to 2010: Member of the EMEA Efficacy Working Party (EWP) Therapeutic Subgroup on Cardiovascular/Pulmonary issues (CVS)

2006 to 2009: Consultant of the AIFA (Italian Agency of Drugs) for: Scientific Advices, Centralized Procedures, Mutual Recognition Procedures, Drug approvals, Post marketing pharmaco-vigilance, Outcome studies for the evaluation of the effectiveness of potentially innovative drugs

2019: included in the register of experts, collaborators and researchers of AGENAS

2019 to date: included in the register of experts, collaborators and researchers of AIFA (Italian Agency of Drugs)

#### Other Relevant Information

2016 Gold Medal of the Italian Association of Hospital Cardiologists (ANMCO)

2017 GIMBE Evidence Award

2017 Commander of the Italian Republic

2019 Gold Medal of the Heart Failure Association of the European Society of Cardiology (ESC)

2019 Hall of Fame-Heart Failure American College of Cardiology

2020 Highly Cited Researcher in the field of Clinical Medicine - 2020

2019 Highly Cited Researcher in the field of Clinical Medicine - 2019

2018 Highly Cited Researcher in the field of Clinical Medicine - 2018